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A NOVEL FIBROBLAST GROWTH FACTOR 1 VARIANT REVERSES 
NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES 
 
Qian Lin 
August 2, 2018 
 
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder 
and is strongly associated with type 2 diabetes (T2D). Our recently engineered FGF1 
partial agonist, carrying triple mutations (FGF1△HBS) exhibits greatly reduced proliferative 
potential, while preserving the full metabolic activity of wild-type FGF1. This study tests 
the preventive and therapeutic effects of FGF1△HBS on NAFLD in db/db T2D and explores 
potential mechanisms. The results showed that administration of FGF1△HBS to 2-month-
old db/db mice for 2 months constantly lowered blood glucose levels, improved insulin 
sensitivity, and lowered liver weight, lipid deposition, and inflammation, along with 
improvement of liver function. Simultaneously, FGF1△HBS treatment prevented diabetes-
induced hepatic oxidative stress along with promoting nuclear translocation of the 
antioxidant transcription factor Nrf2 and elevating its downstream antioxidant genes. In 
addition, FGF1△HBS administration inhibited the activity and/or expression of hepatic 
lipogenic genes including SREBP-1, FAS and SCD-1. Furthermore, FGF1△HBS treatment 
rescued hepatic fatty acid oxidation signaling, including elevated expressions of CPT-1α, 
PPARα and PGC-1α. Moreover, FGF1△HBS treatment greatly increased hepatic  
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phosphorylation of the key energy sensor AMPK, along with upregulating its downstream 
genes ACC and SREBP-1 phosphorylation, indicating that FGF1△HBS regulation of hepatic 
lipid metabolism is associated with AMPK signaling pathway. Mechanistically, hepatic 
cells treated with palmitate (Pal) mimicked the diabetic phenotype of hepatic oxidative 
damage and lipid disorder seen in db/db mice, all of which could be reversed by 
supplementing with FGF1△HBS. Knockdown of Nrf2 by SiRNA completely abolished the 
anti-oxidative capacity of FGF1△HBS but did not affect the beneficial effects of FGF1△HBS 
on Pal-induced lipid metabolic disorder. Whereas, AMPK knockdown by SiRNA 
completely abolished FGF1△HBS ability to prevent Pal-induced hepatic lipotoxicity and 
SREBP-1-mediated lipid metabolic disorder, along with inhibiting Nrf2-mediated 
antioxidative signaling pathway. Most importantly, administration of FGF1△HBS to 9-month-
old db/db mice for 3 months completely reversed the phenotype of NAFLD along with 
activation on Nrf2 and AMPK signaling pathways.  
Our findings demonstrate that, in addition to its potent glucose-lowering and insulin-
sensitizing effects, FGF1ΔHBS can reverse NAFLD in T2D, by its ability to upregulate AMPK 
to activate Nrf2-mediated antioxidative pathway and inhibit SREBP-1-mediated lipid 
metabolic pathway.  
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FGF superfamily and FGF1 subfamily 
Fibroblast growth factors (FGFs) family contains 22 members that are found in 
organisms ranging from the nematodes to humans. Based on the differences in sequence 
homology and phylogeny, these 22 members are commonly grouped into 7 subfamilies: 
FGF1 subfamily (FGF1 and FGF2); FGF7 subfamily (FGF3, FGF7, FGF10, FGF22); FGF4 
subfamily (FGF4, FGF5 and FGF6); FGF8 subfamily (FGF8, FGF17 and FGF18); FGF9 
subfamily (FGF9, FGF16 and FGF20); and FGF15/19 subfamily (FGF19, FGF21 and 
FGF23); and FGF11 subfamily (FGF11,FGF12, FGF13 and FGF14)(1, 2). Among all these, 
the FGFs with low heparin-/heparan sulfate-binding capacities showing the increased 
diffusion from their source are defined as endocrine FGF ligands (FGF19, FGF2 and 
FGF23). Intracellular FGF ligands (FGF11 to FGF14) are not extracellularly secreted and 
perform an intracrine manner to involve in regulating the electrical excitability in neurons. 
The remaining FGFs are the paracrine FGFs ligands that have high affinity for heparan 
sulfate glycosaminoglycan (HSGAG), which lead them to perform a localized manner near 
the sources of their expressions. The FGF1 subfamily includes FGF1 and FGF2, which is 
often called the “prototypical” FGF since they were the first of the FGFs to be isolated and 
identified around 1975(3). 
 
FGF1 gene and gene products  
Fibroblast growth factor 1 (FGF1), also known as acidic fibroblast growth factor 
(aFGF), is a growth factor and signaling protein encoded by the FGF1 gene. The murine 
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and human FGF1 were identified and characterized at the cDNA level in the early 90s. 
The murine gene locates on chromosome 18, and is encoded by a single copy gene,  
which spans over 30 kb of genomic sequence. FGF1 mouse recombinant protein 
produced in E. Coli is a non-glycosylated and single polypeptide chain that contains 161 
amino acids (16-155 a.a) with the molecular mass about 18kDa(4, 5). The human FGF1 
gene resides on chromosome 5q31, which spans over 100 kb. FGF1 human recombinant 
protein produced in E. Coli is also a non-glycosylated and single polypeptide chain that 
contains 140 amino acids with the molecular mass of approximately 15.8kDa.  While the 
mature form of human FGF1 is synthesized as a polypeptide of 155 amino acids, with the 
molecular mass about 17-18 kDa. The mouse FGF1 genomic organization is very similar 
to that of human, since both genes are comprised of three protein coding exons of sizes 
203, 104 and 192 bp. The sizes of the two introns are 11.4 and 4.9 kb(6).  The human 
FGF1 gene has a long 3’-untranslated region (3’-UTR) and a complex 5’-untranslated 
region (5’-UTR). In  3’-UTR, the mouse and human FGF1 genes share 60.4% similarity  in 
sequence, with stretches having more than 80% similarity(7). 
 
FGF1 receptors and their signaling 
The interaction between the ligand FGFs and its receptor is responsible and essential for 
the different biological activities of FGFs. FGF1 mediates biological responses by 
activating and binding to the cell surface FGF receptors (FGFRs). Heparan sulfate/heparin 
acts as a cofactor and is necessary for stable interactions between FGF1 and its FGFRs. 
Several major FGFR proteins (FGFRs 1b, 1c, 2b, 2c, 3b, 3c, and 4) are generated from 
FGFR1, FGFR2, FGFR3, and FGFR4 (FGFR1–FGFR4) genes by alternative splicing, with 
differing ligand-binding specificity , respectively, (8). FGF1 is considered as the universal 
ligand for FGFRs due to its ability to activate and bind with each of the alternatively spliced 
forms of FGFR1–FGFR4 (9, 10), in which FGFR1 is a common receptor for many ligands.
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FGF1-FGFR-heparin ternary complex has been demonstrated to activate four key 
intracellular signaling pathways that play a role in regulating the cell cycle, cell survival 
and apoptosis, namely the PI3k/Akt pathway, Ras/Raf/Mek/Erk pathway, JNK and p38 
MAPK pathway, and STAT3 and NF-κB pathway(11). The endocrine FGFs, such as FGF21, 
FGF15/19, also act their biological regulations in an FGFR-dependent manner with the 
presence of the cofactors (α-klotho or β-klotho) in their respective target tissues.  The 
intracellular FGFs have high sequence identity with other FGF members but do not 
activate FGFRs.   
 
The potential effects of FGF1 in diseases 
FGF1 is a well characterized growth factor among the 22 members in FGF 
superfamily in animals and humans. As a paracrine FGF, FGF1 is involved in the cellular 
regulation of many biological processes such as cell growth, proliferation, migration, 
differentiation, and survival in different cell types(12). Therefore, FGF1 is being explored for 
its therapeutic potential in cardiovascular disorders, ischemia conditions, nerve injuries 
and tissue repair(1). FGF1 shows angiogenic potential in improving myocardial flow, 
regional and global left ventricular function and artery growth and capillary proliferation 
under myocardial ischemia conditions(13-15). FGF1 can also promote nerve regeneration. 
Data indicated that it enabled the functional and axonal regeneration in the transected rat 
spinal cord(16, 17). FGF1 recovered the rat’s forelimb motor function after cord–root junction 
transection (18). In addition, FGF1 stimulated cell proliferation and angiogenesis in vitro 
and in vivo, significantly accelerating the healing of rat burn wounds(19). Although FGF1 is 
a well-known mitogenic factor, the recent discoveries of metabolic roles for FGF1 in 
glucose homeostasis have expanded the functions of those classically known mitogen. In 
2012, Jonker and his colleagues discovered an unexpected metabolic role of FGF1. FGF1 
was demonstrated to transduce of peroxisome proliferator-activated receptor gamma 
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(PPARγ) signaling that mediates the proper nutrient storage coupling in adaptive 
remodeling of adipose tissue(20). In a follow-up study, this group further demonstrated that 
exogenous FGF1 could stimulate the glucose uptake in an insulin-dependent fashion in 
vitro and in vivo(9), much like the non-mitogenic endocrine-acting growth factor, FGF21, a 
candidate drug for obesity and diabetes treatment in clinical trials(21). In recent years, 
additional studies have focused on the potential of FGF1 as a treatment for diabetes and 
diabetic complications.  In general, the mitogenic effects of FGF1 in a variety of diseases 
has been most studied and subject to the clinical trial in humans (14). However, the 
functions and mechanisms of its metabolic effects have been rarely clarified. To the 
advantage of metabolic activity of FGF1 and expand its value inpatients, studies of 
metabolic effects of FGF1 should be expanded. 
 
The effects of FGF1 at type 1 diabetes and type 2 diabetes  
Diabetes is a major and increasing metabolic disease throughout the world, which 
is clinically characterized by chronic hyperglycemia because of the absolute or relative 
insulin insufficiency and dysfunction(22).  The treatment of diabetes is determined by the 
etiopathology and is most commonly subdivided in type 1 diabetes (T1D, beta cell damage 
and/or absolute lack of insulin) and type 2 diabetes (T2D, insulin resistance and/or 
decreased secretion of insulin)(23). 
           FGF1 has not only the mitogenic activity, but also metabolic activity, representing 
a potential novel anti-diabetic therapy. FGF1 was sufficient to attain normoglycemia in the 
severely hyperglycemic mice, such as the genetic induced ob/ob and db/db mice, diet-
induced obese (DIO) and insulin-resistant T2D mice, administered through subcutaneous 
injection(9, 20, 24). However, FGF1 failed to decrease the blood glucose levels in STZ 
induced T1D mouse model whereas pretreatment with FGF1 in STZ mice markedly 
enhanced the glucose-lowering ability of exogenously supplied insulin(9). Additional 
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studies proved that FGF1 couldn’t lower blood glucose levels in STZ-induced T1D model(25, 
26). These results demonstrated that FGF1 might act as an insulin sensitizer. Further, 
intracerebroventricular (i.c.v.) injection of FGF1 also induced sustained diabetes 
remission in leptin-deficient ob/ob T2D mice(24).  Interestingly, i.c.v. injections of FGF1 
reversed the hyperglycemia in T1D rats and promoted the insulin-independent plasma 
glucose lowering effects in T1D by suppressing the hypothalamic–pituitary–adrenal (HPA) 
axis(27). Taken together, the blood lowering effect of FGF1 in T2D, even in T1D, has been 
studied, however, the molecular mechanism of how FGF1 protects from the disorders in 
diabetes still needs further exploration.   
 
The role of FGF1 in diabetic complications 
The rising global prevalence of diabetes accompanies with an high burden of 
morbidity and mortality that is attributable to the chronic hyperglycemia in the 
complications, including a range of microvascular, macrovascular and metabolic 
complications(28). The diabetic complications include cardiovascular disease, stroke, foot 
ulcers, eye damage and chronic kidney disease, which occur in individuals with both T1D 
and T2D. Current therapeutic options for controlling the chronic hyperglycemia can reduce, 
but do not eradicate, the risk of these diabetic complications(29).     
 
The effects of FGF1 on diabetic ulcers 
Diabetic ulcers are responsible for a large percentage of hospitalization among the 
complications of diabetes(30)，which is the major cause of nontraumatic lower extremity 
amputations and disability. Moreover, the mortality of diabetic ulcer is high and healed 
ulcers frequently recur(31).  Diabetic ulcers occur because of various factors, such as some 
intrinsic factors (hyperglycemia, vascular insufficiency and peripheral neuropathy) and 
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extrinsic factors (wound infection, callus formation and traumatic stress)(32-34). The 
management of diabetic ulcers requires protecting the wound by using appropriate 
footwear and antibiotic therapy, providing a moist wound environment or receiving surgical 
debridement and revascularization when necessary(35, 36). However, it is difficult for 
diabetic ulcer patients to stop scratching the wound. They can be irritated by clothing or 
shoes, which increases risk for infection and increases discomfort in patients. Therefore, 
an understanding the pathogenesis of diabetic ulcers and development of more effective 
therapies that can enhance wound healing in diabetes is greatly needed.  
FGF1 is known to exhibit mitogenic activity on various cells from different tissue 
origins including skin, vasculature and liver(1, 11, 37). Many studies have demonstrated that 
topical application of FGF1 stimulated the growth of new blood vessels, proliferation of 
fibroblast and endothelial cells and formation of capillary, suggesting translational 
potential for FGF1 in diabetic ulcers. Early studies demonstrated that FGF1 stimulated 
DNA synthesis in cultured db/db mouse skin biopsy specimens and accelerated wound 
closure in db/db mice at a dose-dependent manner. FGF1 decreased the median time of 
wound closure from 46 d to 16 d and increased granular tissue formation, and re-
epithelialization throughout healing. Although wound healing in FGF1 treated diabetic 
mice was slower than that in nondiabetic littermates, these studies suggest the therapeutic 
potential for FGF1 in promoting healing of dermal ulcers in diabetes(38, 39). Recent studies 
further confirmed that FGF1 enhanced re-epithelialization and proliferation, thereby 
promoted diabetic dermal wound healing in the T2D model of NONcNZO10/LtJ mouse(40).  
The wound healing effect of FGF1 on T1D has also been studied. Xie and 
colleagues utilized an ulcer model in STZ-induced SD rats and topically treated the wound 
surface with FGF1 for 2 weeks. Their data indicated that FGF1 improved ulcer healing on 
day 7 and promoted the re-epithelialization on day 14. FGF1 treatment significantly 
increased capillaries and fibroblast in the wound. This study revealed that FGF1 promoting 
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diabetic wound healing was possibly associated with enhancing the proteins expressions 
of TGF-β and PCNA and preventing oxidative stress(41).  
Furthermore, the modification of FGF1 with chitosan-crosslinked collagen sponge 
(CCCS) or polyethylene glycol (PEGylation) was performed to improve even further the 
diabetic wound healing. Both CCCS and PEGylated modified FGF1 accelerated wound 
healing, collagen generation, increased the TGF-β expression, and increased dermal cell 
proliferation in STZ-induced SD rats(25, 42). These results suggest that modification of FGF1 
could provide a greater effective approach for the therapeutic application of native FGF1 
in clinic. 
 
The effects of FGF1 on diabetic cardiovascular disease 
Diabetic cardiomyopathy (DCM) represents the leading cause of morbidity and 
mortality in diabetic patients. DCM consequent to various structural and functional 
changes, which is characterized by ventricular dilation, enlargement and impaired 
contractility of cardiomyocytes, prominent interstitial fibrosis and diastolic and systolic 
dysfunction(43, 44), eventually leading to heart failure without adequate medical treatment(45). 
At present, there are no effective treatments for this common pathological condition in 
DCM. Current treatments of DCM focus on intense glycemic control of the diet, oral 
hypoglycemics, frequently insulin treat and heart failure symptoms management. Novel 
drugs and new strategies for improving therapeutic and prognostic values in DCM are still 
being explored(46). 
FGF1 is regarded as the angiogenic polypeptide mitogen for cells. It has been widely 
reported that FGF1 promoted the proliferation of vascular endothelial cells and smooth 
muscle cells and stimulated the capillary angiogenesis and migration, and significantly 
minimized infarct size, thus improving cardiac function(47-49). Recent studies have indicated 
that FGF1 has beneficial effects on the heart under diabetic conditions.   
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Zhang C et al. indicated that the native FGF1 and a novel non-mitogenic FGF1 (nm-
FGF1) could prevent DCM by suppressing oxidative stress and cell damage. T1D mice 
treated with nm-FGF1 intraperitoneally for either 1 or 6 months had no impact on body 
weight and blood glucose levels as compared to non-treated diabetic mice. nm-FGF1 
prevented the diabetic-induced cardiac hypertrophy by decreasing the heart weight and 
the mRNA expressions of molecular hypertrophic markers (ANP, ANG and b-MHC) at 1 
month and more obvious reduction at 6 months. The diabetes-induced cardiac fibrosis 
(Collage content, Fibronectin and TGF- β1) were also decreased by nm-FGF1 treatment.  
In vitro studies using nm-FGF1 showed similar cardiac protection as native FGF1.  Both 
native FGF1 and nm-FGF1 prevented the high glucose induced hypertrophy, fibrosis and 
even the DNA oxidative damage in cardiac cells(50, 51). This study provided evidence for 
protection of nm-FGF against DCM, implying that FGF1 might be a potential candidate for 
application in DCM therapy. In a following study, Zhang M et al demonstrated an improved 
FGF1 cardio-protective effect in DCM with nanoparticle modification and ultrasound-
targeted microbubble destruction technique. Similar with previous studies, this study 
showed that FGF1 protected the metabolism abnormalities and myocardial interstitial 
fibrosis, further preventing the left ventricle dysfunction in STZ-induced T1D rats(52, 53). In 
particular, this study indicated that prevention of FGF1 against DCM could be attributed 
to activating PI3K/Akt signaling pathway, in which the phosphorylated Akt reduced the 
myocardial apoptosis via inhibiting the caspaes-3 activity and increasing the expression 
of anti-apoptotic genes (Bax and BCL-2).    
Taken together, these studies demonstrated the preclinical efficacy and 
mechanisms of novel strategies for FGF1 protection against DCM. 
However, it is still too limited to understand the role of FGF1 in cardiac disorders 
under diabetic conditions. More specific role of FGF1 in DCM in T1D and T2D need to be 
further explored.  
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The effects of FGF1 on diabetic nephropathy 
Diabetic kidney disease, also known as diabetic nephropathy (DN), is the leading 
cause of renal failure in patients and is a chronic complication that take place in 20% to 
40% of T1D and T2D(54, 55). DN is a microvascular complication in diabetics and 
characterized by increased glomerular basement membrane width, diffuse mesangial 
sclerosis, microaneurysm, tubulointerstitial fibrosis, and vascular sclerosis. Chronic 
hyperglycemia in diabetes induces dysfunction in various cell types of the kidney, which 
is a risk factor for chronic kidney disease and end-stage renal disease (ESRD), leading to 
progressive renal failure(56). The incidence of DN is increasing each year and a significant 
number of patients who develop ESRD require renal replacement therapies(57, 58). Current 
therapies for DN are aimed at controlling blood glucose and blood pressure levels, 
inhibiting the renal artery stenosis and reducing or abrogating development of albuminuria 
and progression of DN. However, those therapies mentioned above might not be effective 
enough for DN patients who experience progressive kidney function decline resulting in 
ESRD. Hence, novel therapeutic strategies are urgently needed to improve clinical 
management. 
Numerous growth factors and cytokines are implicated in the process of progressive 
renal disease. FGF2 has been proven to involve in the pathogenesis of renal disease by 
inducing the renal fibrosis(59, 60). However, the role of FGF1 in kidney disease has been 
rarely studied, especially in diabetic kidney disease. Previous studies demonstrated that 
FGF1 gene was expressed in the normal human kidneys but was downregulated in 
kidneys from DN patients, suggesting that FGF1 might play a role in kidney function(61-63).  
Recently, Huang et al demonstrated that FGF1 could protect against DN in both T1D and 
T2D through an anti-inflammatory mechanism(26). Interestingly, FGF1 only significantly 
decreased and maintained the blood glucose to the normal level in T2D mice. This is the 
10 
 
 first study to show that the renal protective effects of FGF1 is independent of its glucose-
lowering effects. However, the functions and mechanism FGF1 in DN are still limited.  
 
The effects of FGF1 on diabetic liver disease 
The prevalence of liver damage in patients with diabetes is much higher than that in 
the general individuals. Diabetes is strongly associated with major chronic liver diseases, 
including nonalcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC), 
hemochromatosis, and alcoholic liver disease (ALD)(64). Among these liver diseases, 
NAFLD represents a global epidemic mainly associated with obesity, insulin resistance 
and metabolic syndrome(65). In T2D patients, the prevalence of NAFLD is as high as 75%(66, 
67). Recent studies found that obesity also affected the clinical features of T1D, in which 
about 30% of patients were overweight or obese, thus increasing the susceptibility and 
incidence of NAFLD in diabetes(68). NAFLD is a multifactorial disease, affecting 
extrahepatic organs and regulatory pathways(69). The complex metabolic disturbances in 
NAFLD increase the risk and the difficulty of treatment in diabetes(65, 70, 71).  
In FGF family, the function and mechanism of FGF21 in liver diseases have been 
widely studied. Unlike FGF21, FGF1 has high affinity for heparan sulfate and thus acts 
locally as a mitogenic activator(72-74). The role of FGF1 in metabolic diseases has been 
neglected. Recent studies draw an attention of FGF1 in liver under diabetic conditions. 
Jonker et al. revealed that HFD-fed FGF1–/– mice showed severer hepatic steatosis 
compared to wild-type controls(20). Furthermore, they showed that FGF1 treatment 
decreased hepatic steatosis, increased the hepatic glycogen content and insulin-
sensitivity in DIO mice(9). These results suggest that FGF1 play a critical role in the 
development of liver disease in diabetes. More recently, Liu et al showed that 
administration of FGF1 effectively suppressed the hepatic inflammation in the leptin-
deficient ob/ob mice and the choline-deficient diet mice, two etiologically different models 
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of NAFLD. The suppression of hepatic steatosis was effectively showed in ob/ob mice, 
suggesting that FGF1 could stimulate hepatic lipid catabolism. Because the anti-
inflammatory effects were observed in both the presence and absence of the antisteatotic 
effects, these findings further suggest that the anti-inflammatory property of FGF1 is 
independent of its effect on lipid catabolism. These results indicate that, in addition to its 
potent glucose-lowering and insulin-sensitizing effects, FGF1 could be therapeutically 
effective in the treatment of NAFLD(75). However, the mechanism of FGF1 protection 
against NAFLD remains largely unknown. 
 
The effects of FGF1 on other diabetic complications 
FGF1 also involves in many other diabetic complications that has not been widely 
explored. For example, diabetic retinopathy (DR) is currently the leading cause of 
blindness in T1D and T2D. Lee-Anne Khuu et al observed the lower FGF1 expression in 
DR patients compared to the health subjects. This study firstly demonstrated that FGF1 
was associated with the decreased retinal blood flow in early DR, suggesting that FGF1 
might be predisposing for diabetic vascular diseases(76). Melissa Skibba et al evaluated 
the effects of nmFGF1 on the testes in STZ-induced T1D. They found that nmFGF-1 
ameliorated the diabetic induction of testicular cell death by decreasing the BAX/Bcl-2 
ratio and endoplasmic reticulum stress, and upregulating nuclear factor E2–related factor 
2 (Nrf2) activity(77). The protective effects of FGF1 on other diabetic complications will be 
warranted in future studies. 
 
The limitation of FGF1 in diabetes 
The poor stability 
As the multifunctional proteins, FGFs have low thermal stability and high sensitivity 
to proteases, which limit the potential pharmaceutical use of wild-type FGFs(78).  In addition 
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to the powerful mitogen in numerous different cell types, FGF1 shows the locally restricted 
roles in adipose tissue as well as systemic glucose-lowering activities in vivo that shows 
much closely parallel to those of FGF21(9, 20). However, FGF21 is a well-characterized 
endocrine FGF and circulates as a true endocrine hormone. Whereas the high affinity 
heparin-/heparan sulphate proteoglycan-binding activity and serum lability of FGF1 restrict 
its endogenous actions to local tissues, causing the rapid clearance of exogenous FGF1 
from the systemic circulation(1). Thus, the novel FGF1 delivery system or the advanced 
protein design techniques to obtain new variants of FGF1 for the increased 
thermodynamic stability, prolonged half-life and improved proteolytic resistance are 
necessary, which can provide promising strategies for producing therapeutic effective 
FGF1.  
It has been demonstrated that biopolymer encapsulation effectively sustains the 
controlled release and provides a long-term delivery of growth factors(79, 80). For example, 
Zhang et al used the FGF1 encapsulated nanoparticles (FGF1-NP) to treat DCM resulted 
a greater preventive effect due to the improved stability of FGF1 both during storage and 
in blood circulation. The preventive effects of FGF1-NP on DCM were further promoted by 
using the ultrasound-targeted microbubble destruction strategy, which helped to increase 
the selectivity and efficiency of FGF1-NP delivery to the heart(52, 53). In addition, the 
conjugation of FGF1 to polyethylene glycol (PEG) (PEGylated -FGF1) or chitosan-
crosslinked collagen sponge (CCCS-FGF1) could prolong the release and improve the 
biostability of FGF1, which had been used to accelerate the wound healing in diabetic 
rats(25, 42).   
 
Tumorigenic risk   
Native FGF1 could lead to tumorigenesis, tumor invasion and metastasis, showing 
great tumorigenic risk, especially in tumor latent diseases, such as diabetes(81-83). To 
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decrease the potential side effects of FGF1 caused by its broad-spectrum mitogenic 
activity, a non-mitogenic form of FGF1 had been developed to show decreased mitogenic 
activity(50, 84). Several studies proved that this non-mitogenic FGF1 had preventive effects 
on DCM and diabetic ulcer in T1D.  
Recently, we have engineered a novel FGF1 variant by uncoupling the mitogenic 
and metabolic functions of wild type FGF1 (FGF1WT). This FGF1 partial agonist carrying 
triple mutations (FGF1△HBS) that diminished its ability to induce heparan sulfate (HS)-
assisted FGF receptor (FGFR) dimerization and activation. FGF1△HBS dramatically 
reduced the proliferative activity, while still preserving the full metabolic activity of FGF1WT 
in vitro and in vivo. Most importantly, both FGF1△HBS and FGF1WT could reverse fatty liver 
in db/db mice, implying the potential of FGF1 for liver disease therapy(85).  
 
Conclusion  
FGF1 is involved in the regulation of diverse pathophysiological processes in various 
metabolic syndrome. In addition to the functions of FGF1 in angiogenesis and cell 
proliferation, FGF1 is also associated with the inhibition of inflammation, oxidative stress 
and apoptosis in diabetic complications. Recently, the blood glucose lowering and insulin-
sensitizing capability of FGF1 in diabetes revealed the unexpected metabolic function of 
FGF1, which expanded the functions and potential application of FGF1 in metabolic 
syndrome. The following issues need to be addressed to apply FGF1 in metabolic 
syndrome and its complications: 1) the mechanisms of FGF1 in metabolic syndrome; 2) 
the strong mitogenic activity of FGF1 triggering high tumorigenic risk; 3) the weak stability 







THE PREVENTIVE EFFECTS OF A NOVEL FIBROBLAST GROWTH FACTOR 1 
VARIANT ON NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES 
 
INTRODUCTION 
1. Non-Alcoholic Fatty Liver Disease 
As the global epidemic liver disorder, NAFLD represents a spectrum of liver disease 
that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis, 
ultimately leads to the hepatocellular carcinoma (HCC) and liver failure. NAFLD is the 
pathological fat accumulation in the liver without alcohol intake, that strongly linked to the 
metabolic syndrome including obesity, insulin resistance, dyslipidemia and type 2 diabetes 
(T2D)(69). Nowadays, the complex and strong association between of NAFLD and obesity 
and T2D results to the particularly high prevalence of NAFLD in individuals with T2D, 
corresponding with the worldwide increase in obesity of childhood (86). Current population-
based prevalence of NAFLD is approximately 30–40% in men and 15–20% in women(70).   
 NAFLD is multifactorial diseases, affecting extrahepatic organs and regulatory 
pathways, in which the insulin resistance as a common pathophysiological mechanism(69). 
The excess lipid accumulation in the hepatocyte due to increased inflow of free fatty acids 
and de novo lipogenesis causes insulin resistance, chronic inflammation that, in turn, 
contributes to further abnormal hepatic metabolism. These metabolic disturbances in 
NAFLD increase the risk of progressive liver disease to fibrosis, cirrhosis and HCC, as 
well as the increased risk of T2D(65). As the second hit in NASH, oxidative stress in the 
liver exacerbates inflammation and hepatic fibrosis, and causes impairment of cellular 
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bioenergetics, leading to further disruption of hepatic lipid metabolism and cell death(87-92).  
Nowadays, there are no licensed therapies specifically for the management of NAFLD. 
Current treatments for NAFLD include lifestyle management such as diet control, exercise 
and behavior modification, pharmacological therapies that manage the underlying 
metabolic risk factors, bariatric surgery and liver transplantation of those with end stage 
liver disease(93).  
 
2. Type 2 diabetes 
 Diabetes is a chronic disease that have three major types: type 1 diabetes (T1D), 
T2D, and gestational diabetes. Among these types of diabetes, T2D is the most common 
and prevalent diabetic diseases in the world. The latest study estimated that the worldwide 
number of adult diabetes will increase by 54%, from 285 million to 439 million from 2010 
to 2030, with the increasing rate in youth(94).  In T2D, body cannot use the insulin properly 
which leads to the insulin resistance augmented by lifestyle habits, environmental factors 
and multiple genetic factors(95, 96). The increased action of insulin resistance results in high 
blood glucose also called hyperglycemia. Meanwhile, hyperglycemia may deteriorate both 
insulin resistance and insulin secretion abnormalities, thus enhancing the transition from 
impaired glucose tolerance to diabetes(97). T2D is tightly associated with many 
complications without the appropriate intervention approaches. Hyperglycemia induced 
higher risk for the complications (cardiovascular disease, liver dysfunctions, retinopathy 
and nephropathy) and multiple metabolic disorders (oxidative stress, inflammation and 
endoplasmic reticulum stress). The long-term persistence of metabolic disorders 
increases the risk development of many specific complications. Meanwhile, older diabetic 
patients have a higher burden of comorbidities, diabetes-related complications, physical 
disability, cognitive impairment and malnutrition, and more sensitive to the complications 
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of dysglycemia and polypharmacy. These complications contribute to the excess morbidity 
and mortality in older individuals with diabetes(98-103).   
The prevalence of diabetes mellitus in patients with liver damage is higher compared 
to that in the general population. Diabetes is strongly associated with major chronic liver 
diseases, including NAFLD, chronic hepatitis C (CHC), hemochromatosis, and alcoholic 
liver disease (ALD)(64). Among these liver diseases, NAFLD has been widely studied with 
diabetes, especially in T2D(65). In T2D patients, the prevalence of NAFLD may be as high 
as 75%(66, 67). Nowadays, there has no certain explanation for the substantial increased 
risk of mortality from cirrhosis of any etiology in patients with T2D. In NAFLD, the excess 
of fatty acids and impaired hepatic fatty acid oxidation exacerbate the insulin resistance, 
further increase the hepatic fat accumulation. High glucose levels, obesity and insulin 
resistance in diabetes may be independent factors contributing to progression of NAFLD 
and the ultimate development of cirrhosis(104). These complex metabolic disturbances 
between NAFLD and T2D increased risk and difficulty in treatment of NAFLD in T2D (70, 71) 
(65).  
 
3. The novel fibroblast growth factor 1 variant——FGF1△HBS 
As introduced in the OVERVIEW, FGF1 is a well-known mitogenic factor that has 
been widely studied for its therapeutic potential in cardiovascular disorders, ischemic 
conditions and nerve injury(1). Interestingly, FGF1 recently showed an unexpected 
metabolic function in diabetes by regulating the glucose homeostasis and insulin 
sensitivity(9, 20). However, FGF1 induces hyperproliferation leading to increased 
tumorigenic risk(105), becoming the primary obstacle for its wide application, particularly for 
chronic cancer prone diseases, such as diabetes. Therefore, uncoupling of the mitogenic 




Structure-function relationship study  demonstrated that paracrine FGFs, such as 
FGF1, transmit their signals by binding, dimerizing and activating four FGF receptor 
tyrosine kinases (FGFR1-4) in a heparin sulfate (HS)-dependent fashion(106-108); by 
contrast, endocrine FGFs, such as FGF21, rely on Klotho co-receptors to bind, dimerize 
and activate their cognate FGFRs(12, 
109-112). Paracrine FGFs facilitate 
much stronger FGFRs tyrosine 
transphophorylation and intracellular 
kinase domains activation via HS-
dependent dimerization of FGFRs 
than that of endocrine FGFs via 
Klotho-dependent dimerization of 
FGFRs (113) (Fig. 1).  
According to the understanding 
of the molecular basis for the 
divergence in the biological activity of 
paracrine and endocrine FGFs, we hypothesized that submaximal FGFR activation by a 
weak endocrine FGF-FGFR dimer is sufficient to evoke a metabolic response (such as 
FGF21), whereas full FGFR activation by stable and sustained paracrine FGF-FGFR 
dimerization is required to elicit a mitogenic response (such as FGF1), and the mitogenic 
and metabolic function of paracrine FGF1 could be uncoupled by manipulation of its HS-
associated receptor dimerization. To test this hypothesis, we engineered a novel FGF1 
variant, with reduced ability of inducing HS-dependent FGFR dimerization by replacing 
the three key residues from the HS-binding site of FGF1, namely Lys127, Lys128 and 
Lys133 with residues that are less optimal for HS binding (Lys127Asp, Lys128Gln and 
Lys133Val), termed FGF1△HBS. In an initial study, we found that FGF1△HBS had significantly 
 
Fig 1. The functional differences between 
paracrine and endocrine FGFs. FGF1, as a 
member of paracrine FGFs, has a high affinity 
with heparin sulphate as its coreceptor, which 
acts in a localized manner near the source of 
its expression. While the endocrine FGF, 
FGF21 has β-klotho as its coreceptor with a 
weak affinity with heparin sulphate leading to 
increased diffusion of FGF21 from its source. 
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decreased receptor binding affinity compared to wild-type FGF1 (FGF1WT), which was 
accompanied by significant attenuation of the proliferative potency. While FGF1△HBS 
retained full metabolic activity of FGF1WT, including sensitization of insulin activity, 
improvement of hepatic lipid and glucose metabolism, induction of adipose remodeling, 
and prevention of diabetes-induced systemic, hepatic and adipose inflammation in db/db 
mice, leading to therapeutic efficacy for T2D without mitogenic and hyperplastic activity of 
FGF1WT(85).    
Recent studies demonstrated that high fat diet feeding induced serve hepatic 
steatosis in FGF1–/– mice compared to wild-type controls(20), while liver function and 
pancreatic function appeared normal. Furthermore, FGF1 treatment decreased hepatic 
steatosis and increased the insulin-stimulated Akt signaling in diet-induced obese (DIO) 
mice(9)  . Liu et al indicated the potent antisteatotic and anti-inflammatory effects of FGF1 
on NAFLD in leptin-deficient ob/ob mice(75). In addition, our recent study indicated that 
FGF1 prevented diabetic nephropathy largely via the anti-inflammatory effects in both T1D 
and T2D (26).  These works have brought FGF1 to the forefront as a potential new 
therapeutic agent for insulin sensitization and treatment of T2D, and NAFLD therapy(114).   
However, the functions and mechanism of FGF1-mediated metabolic actions in diabetic 
livers remain largely unknown. To investigate the metabolic activity of FGF1 and explore 
a safe treatment for NAFLD, we therefore hypothesize that the novel mitogenic and 
metabolic function uncoupled variant FGF1△HBS has potential to replace the use of FGF1WT 
to treat NAFLD in T2D.  
 
MATERIALS AND METHODS 
Animal models and drug administration 
 db/db (BKS.Cg-Dock7m +/+ Leprdb/J, Stock # 000642) mice were purchased from 
Jackson Laboratory (Bar Harbor, ME). 2-month-old male db/db mice were administered 
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with FGF1△HBS (0.5 mg/kg) or vehicle phosphate buffered solution (PBS) via 
intraperitoneal injection every other day for 2 months.  At the indicated time-points, the 
blood glucose levels were determined by FreeStyle complete blood glucose monitor 
(Abbott Diabetes Care Inc., Alameda, CA). All mice were housed under a 12:12-h 
light/dark cycle at controlled temperature. All experimental procedures were approved by 
the Institutional Animal Care and Use Committee of the University of Louisville.  
 
Glucose-tolerance tests (GTTs) 
Blood glucose levels were determined as described above. For GTTs, mice were 
fasting for 9h, and then were injected with glucose solution (1 g/kg body weight) 
intraperitoneally. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 min 
after glucose injection.  
 
Biochemical analysis  
Plasma ALT (Cayman Chemical, Ann Arbor, MI) and AST (BioVision, Milpitas, CA) 
levels were measured using enzymatic assay kits according to the manufacturer’s 
instruction. Liver TG was determined using commercially available colorimetric kits 
(Thermo Scientific, Waltham, MA).  Briefly, liver tissues were homogenized in 50mM NaCl 
and the samples were extracted with extract reagent (Chloroform: Methanol=2:1) at 4℃ 
overnight. The next day, the samples were vortexed and centrifuged for 20mins, and the 
lower chloroform layer were collected. Then, 500 µl of lower chloroform layer were placed 
in new tubes and evaporated to dryness in the hood. The dried samples were dissolved 






Liver histopathological analysis 
Liver paraffin sections were processed as previously described(85). Liver tissues 
were fixed in 10% formalin and processed to embed in paraffin. After deparaffinization and 
rehydration, the paraffin sections (5μm) were subjected to hematoxylin and eosin (H&E). 
oXLipid accumulation in the liver tissues was further analyzed by Oil Red O staining. For 
Oil-Red-O staining, frozen sections (10μm) of liver tissues were fixed in 10% formalin for 
10min and rinsed in water. Then the slides were immersed in 60% isopropanol and 
incubated in Oil-Red O solution (saturated Oil Red O isopropanol solution diluted 4:6 into 
60% isopropanol, Sigma-Aldrich) at room temperature for 40mins. The slides were 
washed in 60% isopropanol twice. All the stained sections were quantitated for Oil-Red O 
positive staining area using a Nikon Eclipse E600 microscopy system (Nikon, Tokyo, 
Japan).   
 
Quantitative determination of oxidative stress 
To detect the reactive oxygen species (ROS) levels of diabetic livers after FGF1 
treatment, the cell permeable fluorescent dye, dihydroethidium (DHE, Molecular Probes, 
Eugene, OR) was used to determine the superoxide generation in the liver sections. DHE 
can react with superoxide to form ethidium, which in turn intercalates with DNA and 
produces nuclear fluorescence(115). For DHE staining in frozen liver sections, cryosections 
were incubated with 5 μM DHE for 30 min at 37°C in dark, washed with PBS and captured 
at ×200 magnification (XI 71 Olympus, Tokyo, Japan).    
Malondialdehyde (MDA) is the most frequently used biomarker of oxidative stress in 
many health problems(116). MDA content test was performed to further confirm the ROS of 
diabetic livers after FGF1 treatment. Briefly, 50μl liver tissue lysate was incubate with 8.1% 
SDS, 20% Acetic acid and 0.57%TBA at 90℃ for 70 min. Then cold in ice and centrifuged 
at 4000x g for 15 min.  The fluorescence intensity of final MDA content in each sample 
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was detected by a microplate reader (SpectraMax M3; Molecular Devices, Sunnyvale, CA) 
under specific wavelength conditions (OD=540μm). The final MDA content in each sample 
was calculated as: MDA= (OD of Sample-OD of Standard) *178/pro-concentration 
(mmol/mg).  
 
RNA extraction, cDNA synthesis and quantitative RT-PCR 
Total RNA was extracted from liver tissues with TRIzol reagent (Invitrogen, Carlsbad, 
CA). After quantified using a Nanodrop ND-1000 spectrophotometer, 1µg total RNA was 
used to synthesize first-strand complimentary DNA (cDNA) using reverse transcription kit 
(Promega, WI) following the manufacturer’s instructions. Quantitative RT-PCR reactions 
were performed in duplicate on an ABI Prism 7500HT (PE Applied Biosystems) and were 
normalized to GAPDH. All TaqMan® assay-on-demand primers were from Thermo Fisher 
Scientific Inc. (Grand Island, NY). Sequences were as follows: GAPDH, Mm99999915_g1; 
PAI-1, Mm00436753_m1; TNFα, Mm00443259_g1; VCAM-1, Mm01320970_m1; ICAM-
1, Mm00516023_m1; SREBF1, Mm00550338_m1; FAS, Mm00662319_m1 and SCD-1, 
Mm00772290_m1. 
 
Western blot analysis  
The liver tissues from db/db mice were collected and homogenized. Protein lysates 
from liver tissues were separated using 8-12% SDS-PAGE and electro-transferred onto a 
nitrocellulose membrane. The protein blots were probed with antibodies against HO-1, 
phosphorylated AMPKα/AMPKα, phosphorylated ACC/ACC, and phosphorylated 
SREBP-1 (Cell Signaling Technology, Danvers, MA), CAT, NQO-1, PGC-1α, CPT-1α, β-
actin, and GAPDH (Santa Cruz biotechnology, Dallas, TX), Nrf2, SREBP-1, FAS, SCD-1 
and PPARα (Abcam, Cambridge, MA). The immunoreactive bands were then detected by 
incubating with the secondary antibody (Santa Cruz Biotechnology, Dallas, TX) 
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conjugated with horseradish peroxidase and visualizing using enhanced 
chemiluminescence (ECL) reagents (Bio-Rad, Hercules, CA). The amount of the proteins 




Statistical analyses were performed using the statistical software package 
GraphPad Prism version 6 (GraphPad Software Inc., San Diego, CA, USA). Data are 
expressed as mean ± SEM. Statistical significance was evaluated using the unpaired two-
tailed Student t test or one-way analysis of variance. Differences were considered 
significant at a P value <0.05.   
 
RESULTS  
FGF1△HBS prevents NAFLD in db/db mice 
 
Consistent with the findings in our previous study(85), FGF1△HBS treatment at 0.5 
mg/kg every other day for 2 months greatly lowered blood glucose levels (Fig. 2A), along 
with significant improvement in insulin sensitivity (Fig. 2B, C) in db/db mice. FGF1△HBS 
treatment did not change body weight (Fig. 2D), but markedly lowered liver weight (Fig. 
2E) and prevented liver injury reflected by decreased ALT (Fig. 2F) and AST activity (Fig. 
2G). Furthermore, FGF1△HBS treatment significantly decreased hepatic TG content (Fig. 
2H), showing improved hepatic lipid metabolism.  
Histological examination using H&E staining and Oil Red O staining confirmed the 
antisteatotic effect of FGF1△HBS (Fig. 3A). Hepatic steatosis is associated with hepatic 
inflammation and oxidative stress. In addition to its potent antisteatotic action, FGF1△HBS 
also suppressed hepatic inflammation and oxidative stress reflected by reduced mRNA 
expression of hepatic inflammatory markers including TNFα, PAI-1, ICAM-1 and VCAM-1 
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(Fig. 3B-E) and inhibited super oxide generation (Fig. 3F, G) and MDA production (Fig. 
3H) in db/db mice.  
 
 
Fig. 2 The effects of FGF1△HBS on blood glucose, insulin sensitivity and liver injury 
in 2-month-old db/db mice. (A) The blood glucose over the course of 2 months treatment 
of db/db mice with FGF1△HBS (0.5 mg/kg body weight, every other day). (B and C) The 
Blood glucose levels in IPGTT and integrated area under the curve (AUC) for changes in 
blood glucose levels.  (D and E) The body weight and liver weight changes in db/db mice. 
(F and G) Plasma levels of ALT and AST. (H) Triglyceride contents in livers. Quantitative 





Fig. 3 The preventive effects of FGF1△HBS on hepatic inflammation and oxidative 
stress in 2-month-old db/db mice. (A) Representative images of H&E and Oil Red O 
staining of liver sections (magnification: X200). (B-E) The hepatic mRNA levels of TNFα, 
PAI-1, ICAM-1 and VCAM-1 in db/db mice. (F and G) Representative images of DHE 
staining of liver frozen sections (magnification: X200) and quantitative analysis of 
fluorescent intensity of DHE staining. (H) MDA contents in liver tissues. Quantitative data 
are expressed as mean ± SEM, n=10-13. *P < 0.05 vs. db/db mice. 
 
FGF1△HBS preserves hepatic antioxidant in db/db mice 
To investigate the molecular basis of FGF1△HBS for hepatic antioxidative effects, we 
observed the activation of Nrf2, an essential transcription factor in antioxidative 
responses(117, 118), in FGF1△HBS treated and non-treated db/db mice. As expected, the 
expression of nuclear Nrf2 in db/db mice was elevated significantly after FGF1△HBS 
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treatment for 2 months (Fig. 4A, B). Furthermore, the expression of Nrf2-mediated anti-
oxidative downstream genes catalase (CAT), NAD(P)H Quinone Oxidase 1 (NQO-1) and 
Heme Oxygenase 1 (HO-1), were significantly higher in FGF1△HBS-treated db/db mice 
than those in PBS-treated db/db mice (Fig4. A and C-E). These results indicate that 
FGF1△HBS reduce the hepatic oxidative stress by activating Nrf2-mediated antioxidative 
signaling pathways.  
 
 
Fig. 4 FGF1△HBS activating Nrf2-mediated anti-oxidative signaling pathway in liver 
of 2-month-old db/db mice.  (A) Protein expressions of nuclear Nrf2 and its downstream 
target genes catalase (CAT), heme oxygenase-1 (HO-1) and NAD(P)H dehydrogenase 
(quinone 1) (NQO-1) were determined by Western blot. (B-E) The quantitative analysis of 
nuclear-Nrf2 (n-Nrf2), CAT, NQO-1 and HO-1 in Western blot results by densitometry. 




FGF1△HBS promotes hepatic lipid metabolic signaling in T2D  
To decipher how FGF1△HBS regulates hepatic lipid metabolism in T2D, the key lipid 
metabolism related signaling was evaluated in this study.  As the key factors in de novo 
fatty acid synthesis, FAS, SCD-1 and SREBP-1 at mRNA levels in db/db mice were 
markedly reduced after FGF1△HBS treatment (Fig. 5A), as well as their expression at 
protein levels were inhibited as indicated by western-blot (Fig. 5B-E). In addition, CPT-1α, 
PPARα and PGC-1α, which play major roles in regulating fatty acid oxidation(119), were 
significantly increased in FGF1△HBS-treated db/db mice compared to the control db/db 
mice (Fig. 5B and 5F-H).    
Notably, FGF1△HBS-mediated lipid metabolic regulation was accompanied by a 
significant up-regulation of AMPK phosphorylation in db/db mice (Fig. 5B and 5I).  The 
phosphorylation of ACC and SREBP-1, which are the downstream targets of AMPK, were 
also obviously upregulated by FGF1△HBS treatment in db/db mice (Fig. 5B and 5J, K), 
suggesting that FGF1△HBS regulation of hepatic lipid metabolism was associated with 




Fig. 5 FGF1△HBS regulating lipid metabolic signaling pathway in liver of 2-month-old 
db/db mice.  (A) The hepatic mRNA levels of SREBP-1, FAS and SCD-1 in db/db mice. 
(B) Protein expressions of hepatic lipogenic genes (m/pro SREBP-1, FAS, SCD-1), 
hepatic fatty acid oxidation (CPT-1α, PGC-1α and PPARα) and AMPK signaling pathway 
(p-AMPK/AMPK, p-ACC and p-SREBP-1) related genes were determined by Western blot. 
(C-K) The quantitative analysis of Western blot results by densitometry. Quantitative data 







NAFLD is highly associated with T2D. Considering the interaction between T2D and 
NAFLD, it is certain that NAFLD is an increased risk for the development of T2D, while 
T2D result in the progression of NAFLD to NASH, even to the end-stage of liver disease(64, 
104). However, the therapeutic options for NAFLD with T2D are rather limited.  In the 
present study, we demonstrated that FGF1△HBS, a novel variant of FGF1 uncoupled 
mitogenic and metabolic functions, effectively prevented hepatic steatosis, inhibited the 
oxidative stress via Nrf2-mediated signaling pathway and promoted the hepatic lipid 
metabolism possibly attributed to stimulation of AMPK-mediated signaling pathway in T2D.   
As a paracrine FGF, FGF1 is known to be mitogenic and involved in the regulation 
of diverse pathophysiological processes. The recent discovery of metabolic roles for FGF1 
in adaptive adipose remodeling, metabolic homeostasis and insulin sensitivity has 
expanded the functions of this classically known mitogen(9, 20).  The liver is the critical 
metabolic organ strongly involved in the major metabolic dysfunction in diabetes. 
Increasing studies suggested the role of FGF1 in managing the metabolic dysfunction in 
diabetes (9, 20), and demonstrated anti-steatosis and anti-inflammation effects for FGF1 
protection against NAFLD in diabetes(24, 75). In addition to its potent glucose lowering and 
insulin sensitizing effects, FGF1 would be a promising agent for NAFLD therapy. However, 
the mechanism of FGF1 protection against NAFLD remains largely unknown. In the 
present study, FGF1△HBS was used to define how FGF1 protects against NAFLD in T2D.   
We used 2-month-old db/db mice to determine the preventive effects of FGF1△HBS 
on diabetes-induced fatty liver disease. We demonstrated that FGF1 protected the T2D 
mice from hepatotoxicity by inducing the antioxidant capacity and promoting the lipid 
metabolism in livers. Our results showed that FGF1△HBS significantly attenuated the 
hyperglycemia and promoted the insulin sensitivity in this early-stage db/db mice (Fig. 2 
A-C). Moreover, FGF1△HBS significantly prevented injury, ameliorated the pathologic 
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abnormality and reduced the hepatic lipid accumulation and inflammation in db/db mice 
(Fig.2D-H and Fig. 3A-E). These results further confirmed the blood glucose lowering 
capability and hepatic protective effects of FGF1△HBS were similar as that FGF1WT showed 
in our previous studies(75, 85).   
Oxidative stress refers to various deleterious processes resulting from an imbalance 
between the excessive formation of ROS and limited antioxidant defenses(89), which is a 
major factor responsible for the dysfunction of diabetic livers(88). In the present study, the 
db/db mouse models exhibited robust oxidative stress in liver, indicated by upregulated 
superoxide generation and MDA production, all of which were greatly inhibited by 
FGF1△HBS (Fig.3 F-H). Among the mechanism responsible for the oxidative stress, Nrf2-
mediated signaling pathway plays a critical role in antioxidative responses by upregulating 
multiple antioxidant components(117, 118).  Our findings clearly demonstrated that Nrf2 
activation was upregulated by FGF1△HBS in livers of T2D, as indicated by increased 
nuclear translocation of Nrf2 and upregulation of Nrf2 downstream anti-oxidative genes, 
CAT, NQO-1 and HO-1 (Fig. 4). These finding suggest that the anti-oxidative functions of 
FGF1△HBS are linked to Nrf2 pathway. 
Lipid metabolic disturbance is common in diabetic and NAFLD, which is 
characterized by the excess fatty acid synthesis and impaired lipid catabolism(120, 121). 
Activation of AMPK leads to the phosphorylation of key metabolic enzymes and 
transcriptional regulators that are linked to cellular metabolism, such as glucose uptake, 
fatty acid synthesis and oxidation(122). In addition to reduction of TG and lipid accumulation 
in FGF1△HBS-treatment db/db mice, FGF1△HBS also downregulated the important 
lipogenesis transcription gene, SREBP-1 and its downstream genes, FAS and SCD-1 
(Fig.5A-E).  Moreover, FGF1△HBS significantly upregulated the fatty acid oxidation related 
genes, CPT-1α, PPARα and PGC-1α (Fig.5B and 5F-H). These findings indicate that 
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FGF1△HBS protection against NAFLD is associated with AMPK-mediated lipogenesis 
inhibition and fatty acid oxidation activation.   
These data firstly indicate that the potent preventive effects of FGF1△HBS against 
NAFLD in T2D were strongly associated with the Nrf2 mediated-anti-oxidative pathway 















THE ROLE OF NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 IN 
FIBROBLAST GROWTH FACTOR 1 PROTECTION AGAINST NON-ALCOHOLIC 
FATTY LIVER DISEASE 
 
INTRODUCTION 
1. Oxidative stress in diabetes  
Oxidative stress refers to increased cellular production of reactive oxygen (ROS) 
and nitrogen (RNS) species and impaired clearance of such species by antioxidant 
defense systems that cause damage to lipids, proteins and DNA(123).  Numerous studies 
have indicated that oxidative stress as a key regulator in chronic pathological status 
including cancer, cardiovascular diseases, chronic inflammation, autoimmune disorders 
and diabetes(124).  In particular, increasing evidence has established the role of oxidative 
stress in the development of diabetic complications including diabetic cardiomyopathy, 
retinopathy, nephropathy, neuropathy, and microvascular disease(125). The causes of 
increased oxidative stress in the diabetic complications are partially known by the 
activation of transcription factors, advanced glycated end products (AGEs), and protein 
kinase C(126, 127). In diabetes, the hyperglycemia increases the production of free radicals. 
The excess free radicals and the imbalance of antioxidant defense mechanisms result to 
the damaged cellular organelles and enzymes, increased lipid peroxidation, and insulin 
resistance. These consequences of oxidative stress aggressive cause the damage of 
diabetic complications(126). Meanwhile, oxidative stress has the strong cross-talk with the 
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fibrosis, inflammation, cell death and metabolic stress, which accelerate the tissue 
damage in diseases(128, 129). Therefore, antioxidant therapy has been attractive treatment 
options for diabetes treatment. 
 
2. Oxidative stress in NAFLD  
NAFLD is characterized by excess fatty acid in hepatocytes because of the increased 
inflow of free fatty acids and/or de novo lipogenesis, and decreased fatty acid oxidation 
caused by initial metabolic disturbance. As the “the first hit”, this marked hepatic fat 
accumulation is the risk for the development of NAFLD, which increases the susceptibility  
of the liver to secondary damages(92). Excess lipids in the hepatocyte impairs the 
mitochondria oxidation, inactivates the electron transport chain complexes and stimulates 
peroxisomal and microsomal pathways of fat oxidation. The consequent generation of 
ROS and reactive aldehydic derivatives causes oxidative stress and cell death, via 
multiple factors such as ATP, nicotinamide adenine dinucleotide, glutathione depletion, 
DNA, and lipid damage(89).  There has a vicious circle between the abnormal lipid 
peroxidation and the excess ROS in NAFLD, which continually aggravates the oxidative 
stress and abnormal metabolic regulation, further exacerbates the cell death in NAFLD.  
As the critical “second hit” in NAFLD, oxidative stress also triggers production of 
inflammatory cytokines, causing inflammation leading to the progression of steatohepatitis 
and cirrhosis. This ultimately results in the progress of NAFLD and end-stage liver failure. 
Application of antioxidants suggests a rational curative strategy to prevent the liver injury 
from oxidative stress(88, 130). 
 
3. The role of nuclear factor E2–related factor 2 in diseases 
Nrf2 is a transcription factor that widely distributed in the liver, kidney, muscle, lung, heart 
and other organs. Nrf2 is an important sensor in response to the toxic substances
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and oxidants in the body that is critical for cellular defense mechanisms. In non-stressed 
cells, Nrf2 is inactive in the cytoplasm because of the repressive effect of kelch like ECH 
associated protein 1 (Keap1). Once activated by ROS or electrophilic agents, Nrf2 
translocate into the nucleus and binds to the promoters of a variety genes including the 
genes relevant to anti-inflammation, anti-apoptosis and anti-aging(131). Nrf2 mainly binds 
to antioxidant response element (ARE) to regulate its target genes, such as NAD(P)H 
quinone oxidase 1 (NQO1), heme oxygenase 1 (HO1)(132, 133). The potential protective 
roles of Nrf2-mediated antioxidant activation in diabetic complications, such as diabetic 
nephropathy, cardiomyopathy and limb ischemia, have been widely studied (134-136). 
Recently, Nrf2 pathway has been investigated as a potential target to metabolic 
syndrome, such as obesity, insulin resistance and T2D(137, 138). For example, the liver 
expression of Nrf2 and its downstream genes were decreased in high fat diet fed mice. 
Nrf2 knockout mice have TG and ROS accumulation in liver(139). The Nrf2 activator, such 
as sulforaphane, can activate Nrf2 to inhibit the hepatic oxidative stress and inflammation, 
following with the protection against the hepatic lipid accumulation(140). Xue et al 
demonstrated that adipocyte-specific ablation of Nrf2 in ob/ob mice resulted in reduced 
antioxidant response, but increased plasma triglyceride and aggravated insulin 
resistance(137, 141, 142). All these results demonstrate that in addition to the anti-oxidant 
stress, Nrf2 is also involved in regulating insulin sensitivity and maintaining the glucose 
and lipid homeostasis. 
In the present study, we found that FGF1△HBS significantly ameliorated the hepatic 
oxidative stress in db/db mice associated with the upregulation of nuclear Nrf2, and its 
downstream target genes. Base on the previous studies, we hypothesize that Nrf2-





MATERIALS AND METHODS 
Cell treatment  
The human hepatocellular carcinoma cell line (HepG2) was purchased from the 
American Type Culture Collection. Palmitate (Pal) provided by Sigma-Aldrich (St. Louis, 
MO, USA) was used to mimic diabetes-induced hepatic lipid toxicity including oxidative 
damage and lipid metabolism disorder seen in db/db mice. HepG2 cells were cultured in 
DMEM containing 5.5 mM D-glucose, 10% fetal bovine serum, 100 units/ml penicillin, and 
100 μg/ml streptomycin, and incubated in a humidified atmosphere of 5% CO2 at 37 °C 
and passaged every 2 days by trypsinization. After serum starvation for 24 hours, HepG2 
cells and Nrf2 knockdown-HepG2 cells were treated with 100 μM Pal or control 
with/without insulin in serum free medium for 12 hours, followed by incubation with FGF1WT 
and FGF1△HBS for additional 12 hours, respectively.  Cells were collected for the following 
experiments.  All cell culture experiments were carried out under the guidelines of 
biosafety and approved by the Biosafety Committee of the University of Louisville. 
 
Palmitate preparation 
Pal was dissolved in 50% ethanol solution at 60 °C, and further dissolved in 2% fatty 
acid-free bovine serum albumin (BSA) to make 10 mM Pal stock solution, then filtered and 
stored at -20 °C.   
 
Oil-Red O analysis for cells 
 Cells were seeded in 6-well plate at a density of 104 cells per well. After stimulated 
with Pal in the presence of insulin for 12 hours, followed by incubation with or without 
FGF1WT and FGF1△HBS for additional 12 hours, cells were washed with PBS for three times, 
and then fixed in 4% paraformaldehyde for 20 mins. After washing with PBS three times, 
cells were stained with 0.5% Oil Red O for 10 mins at room temperature. Then the 
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additional Oil Red O was removed by washing with PBS. To quantify Oil Red O content, 
isopropanol (1ml) was added into each well, shaking the plate for 10 mins at room 
temperature. The intensity of Oil Red O content in each sample was detected by a 
microplate reader under specific wavelength conditions (OD=520nm). 
 
Quantitative determination of oxidative stress 
 HepG2 cells were cultured and treated as described above, then incubated with 5 
μM DHE in HBSS medium for 30 minutes at 37°C. Nuclear DHE positive staining indicates 
superoxide generation in cells. The fluorescence intensity was detected using a microplate 
reader (SpectraMax M3; Molecular Devices, Sunnyvale, CA) under specific wavelength 
conditions (excitation, 518 nm; fluorescence, 605 nm).   
For MDA analysis in vitro, 50μl proteins from cells were incubate with 8.1% SDS, 
20% Acetic acid and 0.57%TBA at 90℃ for 70 mins. Then centrifuged at 4000x g for 15 
mins. The calculation of the fluorescence intensity finally MDA content in each sample 
was same as that performed in vivo. 
 
SiRNA transfection  
knockdown of Nrf2 was performed using small interfering RNAs (siRNAs) targeting 
Nrf2 and control siRNA (Santa Cruz Biotechnology, CA) according to the manufacturer’s 
protocol. HepG2 cells were seeded at a density of 20 X 104 cells/well in 6-well plates and 
were transfected with Nrf2-siRNA using lipofectamine 2000 reagent (Invitrogen) at a final 
concentration of 100 nmol/L in Opti-MEM (GIBCO BRL) for 6 hours, respectively. Then 






Triglyceride content determination in cells 
Cells were seeded in 6-well plate at a density of 20X104 per well. After stimulated 
with Pal and treated with FGF1WT and FGF1△HBS in the present of insulin, cells were 
washed with PBS for three times and then incubated with 0.3 ml, 0.25M NaOH for 10 mins. 
Cells were scraped into the tube and incubated with hexane/isopropanol mixture (3:1) for 
1 hour, then centrifuged at 10000g for 5 mins and then transferred the supernatants to a 
new tube. The supernatant was evaporated at room temperature overnight. A TG kit 
(Thermo Scientific, Waltham, MA) was used to solubilize the lipid pellet. After incubation 
with TG buffer for 10 mins at 37℃, the levels of TG content in each well was detected by 
a microplate reader under specific wavelength conditions (OD=505 nm). 
 
Western blot analysis 
The above cultured HepG2 cells were collected and lysed. Lysate proteins from liver 
tissues and cells were separated using 8-12% SDS-PAGE and electro-transferred onto a 
nitrocellulose membrane.  
 
Statistical analysis 
Statistical analyses were performed using the statistical software package, 
GraphPad Prism version 6, (GraphPad Software Inc., San Diego, CA, USA). Data are 
expressed as mean ± SEM. Statistical significance was evaluated using the unpaired two-
tailed Student t test or one-way analysis of variance. Differences were considered 








FGF1 prevents Pal-induced oxidative stress in an insulin-dependent manner in 
HepG2 cells 
As shown in DHE staining result, the hepatic superoxide production was higher in 
Pal-induced HepG2 cells compared to the Control. The ROS accumulation in Pal-induced 
HepG2 cells was not decreased by FGF1WTor FGF1△HBS (FGF1) treatment alone, but 
obviously inhibited by FGF1 treatment in the present of insulin (Fig. 6A).  In agreement 
with DHE result, FGF1 effectively inhibited the oxidative stress in an insulin dependent 
manner in Pal-induced HepG2 indicated by MDA analysis (Fig. 6B, C).  Compared to the 
control, Pal significantly suppressed the expression of nuclear Nrf2 in HepG2 cells. 
Treatment with FGF1 significantly preserved Pal-induced reduction of nuclear Nrf2 in 
HepG2 cells. The marked upregulation of nuclear Nrf2 was shown in Pal-induced HepG2 
cells after FGF1 treatment with insulin, which was accompanied by a significant increase 
in expression of its downstream anti-oxidative genes, CAT, HO-1 and NQO-1 (Fig. 7). 
These results suggest that FGF1 prevents Pal-induced hepatic oxidative stress possibly 





Fig. 6 FGF1 preventing from Pal-induced hepatic oxidative stress in HepG2 cells. 
(A and B) Representative images (magnification: X100) and quantitative analysis of 
fluorescent intensity of DHE staining in Pal-induced HepG2 cells. (C) MDA content. 
Quantitative data are expressed as mean ± SEM, n=3-5. #P<0.05 vs. Ctrl; *P < 0.05 vs. 





Fig. 7 FGF1 preventing from Pal-induced hepatic oxidative stress via activating 
Nrf2-mediated anti-oxidative signaling pathway in HepG2 cells. (A) The protein 
expressions of nuclear Nrf2 and Nrf2 target genes CAT, HO-1 and NQO-1 in HepG2 cells 
were determined by Western blot. (B-E) The quantitative analysis of Western blot results 
by densitometry. Quantitative data are expressed as mean ± SEM, n=3-5. #P<0.05 vs. Ctrl; 
*P < 0.05 vs. Pal; &P < 0.05 vs. Pal+Ins; $P < 0.05 vs. Pal+FGF1△HBS or Pal+FGF1WT. 
 
FGF1 prevents Pal-induced lipotoxicity in an insulin-dependent manner in HepG2 
cells  
 Pal treatment caused a clear increase of TG accumulation in HepG2 cells 
compared with the Control (Fig. 8A).  Furthermore, both FGF1△HBS and FGF1WT treatment 
prevented Pal-induced lipid accumulation in HepG2 cells in an insulin-dependent manner, 
reflected by intracellular TG content analysis and Oil-Red O staining (Fig. 8A and 8B). In 
the presence of insulin, FGF1 dramatically decreased the expression of m/proSREBP-1, 
FAS and SCD-1 (Fig. 9A-D) and increased the expression of CPT-1α, PGC1α and PPARα 
(Fig. 9A, E-G). In addition, the dramatic reduction of phosphorylated AMPK by Pal in 
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HepG2 cells was preserved by FGF1 treatment, along with the increased phosphorylation 
of its downstream genes ACC and SREBP-1 (Fig. 9A, H-J).  
 
 
Fig. 8 FGF1 preventing from Pal-induced hepatic lipotoxicity in HepG2 cells. (A) 
Triglyceride contents. (B) Representative images of Oil Red O staining and Oil Red O 
content analysis. Quantitative data are expressed as mean ± SEM, n=3-5. #P <0.05 vs. 





Fig. 9 FGF1 inhibiting lipogenesis and promoting lipid oxidation signaling in Pal-
HepG2 cells. (A) Protein expressions of lipogenic genes (m/pro SREBP-1, FAS, SCD-1), 
fatty acid oxidation (CPT-1α, PGC-1α and PPARα) and AMPK signaling pathway (p-
AMPK/AMPK, p-ACC/ACC and p-SREBP-1) in HepG2 cells were detected by Western 
blot. (B-J) The quantitative analysis of Western blot results by densitometry. Quantitative 
data are expressed as mean ± SEM, n=3-5. #P <0.05 vs. Ctrl; *P < 0.05 vs. Pal; &P < 0.05 




Nrf2 silencing abolishes the protective effects of FGF1 against oxidative stress 
but not lipotoxicity 
In addition to playing a central role in responding to oxidative stress, Nrf2is also a 
target for regulating lipid metabolism(143).  Nrf2 knockdown significantly aggravated the 
oxidative damage compared to Control-siRNA group, neither FGF1△HBS nor FGF1WT 
decreased the MDA content after Nrf2 knockdown in HepG2 cells (Fig. 10A). Moreover, 
FGF1 did not affect the protein levels of nuclear Nrf2, HO-1, CAT and NQO-1 in Pal-
induced HepG2 cells transfected with Nrf2-siRNA compared to Control-siRNA group 
(Fig. 10B-G), suggesting Nrf2 silencing abolished the preventive effects of FGF1 from 
Pal-induced oxidative damage. However, Nrf2 knockdown did not affect FGF1 
prevention from TG accumulation in Pal-induced HepG2 cells (Fig. 11A). Meanwhile, 
FGF1 inhibiting Pal-induced upregulation of m/pro-SREBP-1, FAS, and SCD-1 also was 
not affected by Nrf2 knockdown in cells (Fig. 11B-E). Taken together, our results indicate 
that Nrf2 is not required for the inhibitory effects of FGF1 on Pal-induced lipid disorder in 




Fig. 10 Knockdown of Nrf2 in the HepG2 cells attenuated the beneficial effects of 
FGF1 on Pal-induced oxidative stress in HepG2 cells. (A) MDA contents in Pal-induced 
HepG2 cells. (B) The expressions of nuclear Nrf2, total Nrf2 (t-Nrf2), HO-1, CAT and NQO-
1 were determined by Western blot. (C-G) The quantitative analysis of nuclear Nrf2, t-Nrf2 
and HO-1 western blot results by densitometry. Quantitative data are expressed as mean 
± SEM, n=3-5. #P <0.05 vs. Control-Control-SiRNA; *P < 0.05 vs. Pal-Control-SiRNA; &P 




Fig. 11 Knockdown of Nrf2 cells affect the beneficial effects of FGF1 on Pal-induced 
lipiotoxicity in HepG2 cells. (A) TG content in HepG2 cells. (B) Protein expressions of 
lipogenic genes (m/pro SREBP-1, FAS, SCD-1) were determined by Western blot. (C-E) 
The quantitative analysis of m/pro SREBP-1, FAS, SCD-1 Western blot results by 
densitometry. Quantitative data are expressed as mean ± SEM, n=3-5. #P <0.05 vs. 
Control-Control-SiRNA; *P < 0.05 vs. Pal-Control-SiRNA; &P < 0.05 vs. Control-Nrf2-
SiRNA; $P < 0.05 vs. Pal-Nrf2-SiRNA. 
 
DISSISION 
Among the many potential pathogenic mechanisms responsible for the progression 
of NAFLD, oxidative stress is recognized as a secondary hit driving the pathogenesis of 
NAFLD. Oxidative stress exacerbates hepatic inflammation and fibrosis, leading to further 
disruption of hepatic lipid metabolism(87-92). It suggests a close relationship between 
dysregulated lipid homeostasis and oxidative stress in the pathogenesis of NAFLD(142, 143). 
45 
 
In the intracellular signaling system that regulates oxidative stress responses, Nrf2 
is a well-known master regulator of the cellular adaptive response to oxidative damage(137).  
Emerging evidence indicated that, in addition to regulating hepatic antioxidant defenses, 
Nrf2 plays a critical role in regulating the hepatic energy metabolism pathways(137, 141, 144).  
To further understand the protective effects of FGF1 against lipotoxicity in hepatocytes, 
Pal was used to mimic T2D-induced lipotoxicity to explore the protective mechanism of 
FGF1(145, 146).   
Pal-induced HepG2 cells successfully mimicked the phenotype of diabetes-induced 
oxidative stress and lipid toxicity. Both FGF1△HBS and FGF1WT protected Pal-induced 
HepG2 cells against hepatic lipotoxicity in an insulin dependent manner (Fig.6 and Fig.8), 
following with a significant increase in Nrf2 signaling and AMPK signaling (Fig. 7 and Fig. 
9). These results further confirmed the protection of FGF1 against NAFLD was associated 
with Nrf2- and AMPK-mediated signaling pathways. 
Accordingly, we detected the role of Nrf2 for FGF1 treatment in NAFLD. As expected, 
FGF1 could not reverse Pal-induced ROS accumulation after Nrf2 silencing in HepG2 cells 
after Nrf2 knockdown (Fig. 10). This result suggests that Nrf2 play a critical role in the anti-
oxidative stress action of FGF1 in hepatic cells. However, FGF1 administration still 
attenuated lipid accumulation and lipogenesis genes expression in Pal-induced HepG2 
cells with Nrf2 knockdown (Fig. 11). These results suggest that Nrf2 silencing was not 









THE ROLE OF AMP-ACTIVATED PROTEIN KINASE α IN FIBROBLAST GROWTH 
FACTOR 1 PROTECTION AGAINST NON-ALCOHOLIC FATTY LIVER DISEASE 
 
INREODUCTION 
1. Lipid metabolism in liver 
Lipid metabolism is a process of lipid synthesis and degradation in cells. The liver is 
a central metabolic organ in the regulation of glucose and lipid metabolism. Lipid 
metabolism in hepatocytes can be summarized by three processes: (1) lipid absorption, 
including lipids and fatty acids uptake and fatty acid synthesis (de novo lipogenesis); (2) 
lipid storage, including triglyceride synthesis and lipid droplets formation; and (3) lipid 
catabolism, including lipolysis, β-oxidation, and the very low-density lipoproteins (VLDL) 
secretion(120, 121). Lipid metabolic disorders are characterized by a change in the 
concentration and/or composition of lipoproteins in the blood, such as low-density 
lipoprotein (LDL), cholesterol, VLDL, and TG(147).  
 
2. Lipid metabolic dysregulation in diabetes and NAFLD  
Lipid metabolic dysregulation is common in diabetic and NAFLD patients. Insulin 
deficiency, insulin resistance, obesity, and genetic factors are related the lipoprotein 
production and catabolism. T2D has an increased prevalence of lipid abnormalities. T2D 
patients usually show decreased HDL level and elevated VLD. LDL levels is usually not 
significantly different in T2D patients compared with nondiabetic individuals(148). The liver 
plays a particularly important role in lipid metabolism that involves in the lipoprotein
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synthesis, lipid transport and is the main site for fatty acid oxidation and ketone body 
formation. NAFLD is characterized by excessive fat accumulation in the liver, showed by 
the increased flux of free fatty acids (FFA), lipoprotein lipase (LPL) and TG 
accumulation(149).  
Generally, the mechanism contributing to the pathogenesis of NAFLD includes the 
extrahepatic mechanisms and intrahepatic mechanisms. The extrahepatic mechanism 
includes the adipose tissue that increases FFA transporting to the liver and many dietary 
macro- and micro-nutrients, such as saturated fatty acids, polyunsaturated fatty acids (n-
3PUFAs), and carbohydrate protein, participating in the increased de novo fatty acid 
synthesis. While some key enzymes, such as acetyl-CoA carboxylase (ACC), fatty acid 
synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1) and diacylglycerol acyltransferase-
2 (DGAT-2), and some key transcription factors, such as sterol regulatory element-binding 
protein 1 (SREBP-1), insulin induced gene-1 (Insig-1) and carbohydrate-responsive 
element-binding protein (ChREBP), play important roles in de novo lipogenesis as the 
intrahepatic mechanisms in NAFLD(66). The excessive fat depositions in the liver not only 
due to increased fatty acid synthesis, but also affected by the decreased mitochondrial β-
oxidation, decreased clearance of VLDL or these factors in  combination(150). Studies 
showed that hepatic fat from the de novo pathway is less than 5% under basal conditions, 
however, up to 30% of fat deposited from de novo lipogenesis in the liver under 
pathological conditions(66, 151). 
In addition, lipid metabolic disturbance in liver is also associated with the 
Inflammation, oxidative stress, fibrosis and ER stress(152), increasing the complexity of the 
molecular and pathological mechanism of liver. It is still difficult to understand the lipid 
metabolism in the development of NAFLD. The common management of lipid disorder in 
diabetes and NAFLD is directed at improving glycemic control, altering dietary composition, 
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and reducing calories intake(153). Hence, study on drug development for lipid metabolic 
regulation in liver is of great importance to the prevention and treatment of NAFLD. 
 
3. The role of AMP-activated protein kinase (AMPK) in diseases 
The AMP-activated protein kinase (AMPK) is a ubiquitously expressed 
serine/threonine protein kinase that is well-known as a central regulator of multiple 
metabolic pathways and may have therapeutic importance for treating obesity, insulin 
resistance, T2D, NAFLD, and cardiovascular disease. AMPK plays a critical role in 
increasing glucose uptake, fatty acid oxidation (FAO), mitochondrial biogenesis, and 
autophagy, and suppressing the synthesis of fatty acids, cholesterol, via regulating 
metabolic related proteins(154-156). AMPK is a heterotrimeric complex composed of catalytic 
α-subunit (α1, α2) and regulatory β- (β1, β2) and γ-subunits (γ1, γ2, γ3) with multiple 
isoforms for each subunit. These subunits are encoded by distinct genes and have unique 
tissue specific expression profiles(122, 157). Compelling evidences indicate that AMPK plays 
an essential role in the development of NAFLD. Liver specific overexpression of AMPK α1 
in T2D protected against the steatosis reflected by reduction of lipogenic gene expression 
and TG content(158). Overexpression of AMPK α1 in hepatocytes not only increased the 
fatty acid clearance via mitochondrial FAO as indicated by CPT-1 expression, but also 
decreased TG accumulation(159). Liver-specific knockout of AMPKα2 showed 
hyperglycemia and elevated hepatic glucose production compared to controls(160).  
Mechanistically, AMPK promotes the lipid metabolism in liver via regulating the important 
enzymes and transcription factors of lipid biosynthesis and FAO, such as FAS, ACC, 
SREBP-1 and SREBP-2(155, 161). AMPK also regulates some mediators for the control of 
total mitochondrial content, quality, and function, such as PPAR-γ1 coactivator (PGC-1α) 
and histone deacetylases (HDAC) and the unc-51-like autophagy activating kinase 
1(ULK1)(162). In addition to altering metabolic pathways, AMPK also triggers key proteins 
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in controlling inflammatory cell proliferation, ER stress and oxidative stress pathways, 
including NF-kB, mTOR, and Nrf2 activity(133, 163, 164). Therefore, AMPK would be a critical 
therapeutic target for NAFLD. 
The relationship between AMPK and Nrf2-mediated metabolic regulation has been 
investigated for many years.  Many recent studies found that Nrf2 and AMPK interacted 
to regulate each other under different pathological and physiological conditions. For 
example, Mo et al showed that berberine activated the AMPK and Nrf2 pathway against 
inflammation in both lipopolysaccharide-shocked macrophages and mice, in which AMPK 
worked at the upstream of Nrf2(165). However, Sids et al demonstrated that Nrf2 was 
independent of AMPK signaling pathways in human hepatocarcinoma cells treated with 
AMPK activator AICAR(117). In Yang’s study, alpha-lipoic acid improved high-fat diet-
induced hepatic steatosis by modulating Nrf2-mediated antioxidation and 
SIRT1/LKB1/AMPK pathway-mediated lipid metabolism(87). Thus, the interaction of Nrf2 
and AMPK has not been clearly clarified, especially after stimulation by FGF1.  
 In this study, our results showed that FGF1 prevented NAFLD along with 
upregulation of Nrf2- and AMPK-mediated signaling pathways. However, Nrf2 silencing 
only abolished FGF1 protection against Pal-induced hepatic oxidative stress. Thus, we 
hypothesized that AMPK-mediated signaling pathway would be critical for FGF1 protection 
against NAFLD in T2D. 
 
MATERIALS AND METHODS 
Primary mouse hepatocyte isolation and culture 
Primary mouse hepatocytes were isolated using a method described previously(166). 
Briefly, Hepatocytes were isolated from C57/BL6J mice by in situ digestion under aseptic 
conditions. The liver was perfused with ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-
tetraacetic acid (EGTA) solution (10 mM HEPES, 5 mM glucose, 138 mM NaCl, 5.4 mM 
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KCl, 28.3 mM NaHCO3, 0.12 mM Na2HPO4, 0.56 mM NaH2PO4 and 0.5 mM EGTA , pH 
7.4) and collagenase solution (10 mM HEPES, 138 mM NaCl, 5.4 mM KCl, 28.3 mM 
NaHCO3, 0.12 mM Na2HPO4, 0.56 mM NaH2PO4, containing 0.0857 U/ml collagenase 
D (Roche Diagnostics, Indianapolis, IN) and 3.8 mM CaCl2, pH 7.4). The isolated 
hepatocytes were washed with HBSS (Gibco BRL, Life Technologies, Inc., NY) and then 
were cultured at a density of 20 × 104 cells/dish after the cell viability was assessed by the 
trypan blue exclusion test. Primary mouse hepatocyte was cultured in Waymouths 
medium supplemented with 5% (w/v) fetal bovine serum (FBS) (Gibco BRL, Life 
Technologies, Inc.), antibiotic-antimycotic (Gibco 100 units/mL of penicillin, 100μg/mL of 
streptomycin, 0.25μg/mL of Fungizone) and ITS supplement (VWR).  
After AMPKα1/2-siRNA transfection, primary mouse hepatocytes were induced by 
100 μM Pal with or without FGF1WT and FGF1△HBS treatment for 12 hours as described in 
HepG2 cells. Then cells were collected to observe the oxidative stress and lipid 
metabolism after FGF1WT and FGF1△HBS administration when AMPK silencing.  
 
AMPKα1/2-siRNA transfection 
Knockdown of AMPKα1/2 was performed using small interfering RNAs (siRNAs) 
targeting AMPKα1/2 (Santa Cruz Biotechnology, CA) according to the manufacturer’s 
protocol. The scramble siRNA sequences were used as control. HepG2 cells or primary 
hepatocytes were seeded at a density of 20X104 cells/well in 6-well plates were 
transfected with AMPKα1/2-siRNA using lipofectamine 2000 reagent (Invitrogen) at a final 
concentration of 100 nmol/L in Opti-MEM (GIBCO BRL) for 6 hours, respectively. Then, 







Statistical analyses were performed using the statistical software package, 
GraphPad Prism version 6, (GraphPad Software Inc., San Diego, CA, USA). Data are 
expressed as mean ± SEM. Statistical significance was evaluated using the unpaired two-
tailed Student t test or one-way analysis of variance. Differences were considered 
significant at a P value <0.05.    
 
RESULTS 
AMPK silencing abolished the protective effects of FGF1 against Pal-induced 
oxidative stress and lipid disorder in primary hepatocytes 
            To detect the role of AMPK in FGF1-mediated inhibiting effects on hepatic 
lipotoxicity, AMPK knockdown was performed using specific siRNA against AMPKα in 
mouse primary hepatocyte. Compared to control-siRNA, AMPKα-siRNA-mediated 
knockdown of AMPKα remarkably reduced AMPK expression (Fig. 12B,C) and 
phosphorylation (Fig. 12B,D), which was accompanied by downregulation of its 
downstream target genes ACC (Fig. 12B,F) and SREBP-1 (Fig. 12B,E) phosphorylation. 
Furthermore, knockdown AMPKα dramatically aggravated Pal-induced lipid 
accumulation, reflected by increased TG content compared with control-siRNA treatment 
(Fig. 12A), and completely abolished the preventive effects of both FGF1△HBS and 
FGF1WT against lipid accumulation (Fig. 12A) and lipogenic genes upregulation (Fig. 
12B,H-J), and FAO gene downregulation. More importantly, knockdown AMPKα also 
aggravated Pal-induced oxidative stress, reflected by MDA production compared with 
control-siRNA treatment (Fig. 13A), and completely abolished the preventive effects of 
both FGF1△HBS and FGF1WT against oxidative stress-induced by Pal in primary 
hepatocytes (Fig. 13A). This was accompanied by almost complete attenuation of Nrf2 
nuclear translocation (Fig. 13B,C) and its downstream genes expression (Fig. 13B,D-F) 
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under basal and both FGF1△HBS and FGF1WT stimulated conditions, but without 
significant effects on total Nrf2 (Fig. 13B,D) and CAT (Fig. 13B,G) expression. These 
results support the notion that AMPK plays a central role in FGF1 preventing from Pal-





Fig. 12 AMPK silencing abolished the protective effects of FGF1 against Pal-
Induced lipotoxicity in primary mouse hepatocyte. (A) Triglyceride contents. (B) Protein 
expressions of AMPK signaling pathway (p-AMPK/AMPK, p-ACC and p-SREBP-1), 
PPARα and lipogenic genes (m/pro SREBP-1, FAS, SCD-1) in primary mouse hepatocyte. 
(C-J) The quantitative analysis of Western blot by densitometry. Quantitative data are 
expressed as mean ± SEM, n=3-5. #P <0.05 vs. Control-Control-SiRNA; *P < 0.05 vs. Pal-




Fig. 13 AMPK silencing abolished the protective effects of FGF1 against Pal-
Induced oxidative stress in primary mouse hepatocyte. (A) MDA contents in primary 
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hepatocyte. (B) Protein expressions of Nrf2-mediated anti-oxidative stress signaling 
pathway (n-Nrf2, t-Nrf2, HO-1, NQO-1 and CAT) in primary mouse hepatocyte. (C-G) The 
quantitative analysis of n-Nrf2, t-Nrf2, HO-1, NQO-1 and CAT Western blot results by 
densitometry. Quantitative data are expressed as mean ± SEM, n=3-5. #P <0.05 vs. 
Control-Control-SiRNA; *P < 0.05 vs. Pal-Control-SiRNA; &P < 0.05 vs. FGF1WT-Control-
SiRNA; $P < 0.05 vs. FGF1△HBS -Control-SiRNA. 
 
DISSISION 
AMPK is a central metabolic regulator of lipid and glucose metabolic homeostasis 
in many metabolic diseases. Activation of AMPK leading to the phosphorylation of key 
metabolic substrates and transcriptional regulators plays a critical role in fatty acids 
synthesis, glucose uptake, FAO and mitochondrial biogenesis. In addition, AMPK also 
involves in the regulation of the inflammation, oxidative stress and apoptosis through direct 
phosphorylation of multiple targets(122, 154, 167).   
The results in Chapter III indicated that knockdown of Nrf2 abolished the anti-
oxidative stress effects of FGF1 but did not affect the inhibition on lipid accumulation and 
upregulation on AMPK-signaling pathway of FGF1 in hepatic cells. In this study, we further 
demonstrated that knockdown of AMPKα abolished not only FGF1 protection against Pal-
induced oxidative stress and Nrf2-mediated antioxidative signaling pathway, but also 
FGF1 protection against Pal-induced lipid disorder and lipid metabolic signal dysregulation 
(Fig.12A and 13A).  
Collectively, these findings suggest that AMPK is required for FGF1 protection 




THE THERAPTUTIC EFFECTS OF A NOVEL FIBROBLAST GROWTH FACTOR 1 
VARIANT ON NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES 
 
INTRODUCTION 
With the increasing incidence of obesity and T2D in every age group, the global 
prevalence of NAFLD varies from 20-30%(168). A report from the Mayo Clinic pointed out 
that people in their age of 40s and 50s show the highest incidence of either NAFLD or 
T2D, which can be mainly explained by the delayed diagnosis(168). In NAFLD, most people 
have no symptoms until they come to the medical attention.  The progression of NAFLD 
can be prevented in patients at the early stage with symptoms of enlarged liver, fatigue 
and pain in the abdomen. Without the timely intervention, inflammation and scarring of the 
liver can occur over time. The advanced symptoms that are not easy to be cured include 
the abdominal swelling, enlarged blood vessels and spleen, yellow skin and eyes(169). In 
T2D, the signs and symptoms often develop slowly. People can have T2D and not know 
it for years until an acute medical condition occurs because of the unawareness of the 
diabetic symptoms including the increased thirst and hunger, weight loss, fatigue and 
blurred vision(170-174). Patients may take attention to T2D management only when the 
complications appear. 
All aged diabetic patients have a high burden of comorbidities, and more susceptible 
to complications, as well as patients with NAFLD. T2D is associated with chronic 
complications throughout the body and with significantly accelerated rates of several 
microvascular complications such as nephropathy, retinopathy, and neuropathy, and 
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atherosclerosis, leading to the physical disability, cognitive impairment and malnutrition 
(175, 176). NAFLD progresses to NASH in about 20% of cases, of which 20–25% may 
progress on to hepatic fibrosis and cirrhosis(93). A small proportion of individuals develop 
advanced fibrosis, cirrhosis can lead to fluid buildup in the abdomen, veins swelling, 
drowsiness and worsen to hepatic encephalopathy, even end stage liver disease, 
hepatocellular carcinoma (HCC)(177). All these complications contribute to the excess 
morbidity and mortality in aged individuals with NAFLD and diabetes. 
Therefore, clinically, it is urgent and important to pay more attention to discover 
therapeutic drugs. To ensure greater clinical relevance, we thus choose the aged db/db 
model to determine the therapeutic effects of FGF1△HBS against NAFDL in T2D.    
 
MATERIALS AND METHODS 
Animal model  
Late-stage 9-month-old male db/db mice were administered with FGF1△HBS or PBS 
via intraperitoneal injection (0.5 mg/kg) every other day for 3 months. At the indicated time-
points, the blood glucose levels were determined by FreeStyle complete blood glucose 
monitor (Abbott Diabetes Care Inc., Alameda, CA). All mice were housed under a 12:12-
h light/dark cycle at controlled temperature. All experimental procedures were approved 
by the Institutional Animal Care and Use Committee of the University of Louisville. All the 




Therapeutic Effects of FGF1△HBS on NAFLD in aged db/db mice 
         To explore the clinic translational potential, we further investigate whether 
FGF1△HBS is sufficient to reverse the exacerbated liver injury in late-stage db/db T2D 
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mice. We treated 9-month-old db/db mice with FGF1△HBS (0.5 mg/kg body weight) every 
other day for 3 months. Pharmacological administration of FGF1△HBS almost completely 
normalized the blood glucose levels (Fig. 14A) and significantly improved insulin 
sensitivity (Fig. 14B, C). FGF1△HBS treatment slightly reduced body weight (data not 
shown), but markedly reduced liver seizes and weight (Fig. 15A, B) and reversed liver 
steatosis (Fig. 15C) and lipid accumulation (Fig. 15D). Furthermore, FGF1△HBS treatment 
also prevented liver injury (Fig. 15E, F) and suppressed hepatic inflammation (Fig. 15G-
J) and oxidative stress (Fig. 16A).  
          To validate the universal mechanism of the efficacy of FGF1△HBS on NAFLD, the 
hepatic antioxidative and lipid metabolic markers were also examined. Likewise, 
FGF1△HBS treatment markedly increased Nrf2 nuclear translocation (Fig. 16B, C) and 
upregulated the expression of its downstream target genes (Fig. 16B, D-F). Furthermore, 
FGF1△HBS treatment significantly suppressed the activation of SREBP-1 (Fig. 17A, B) 
and the expression of its downstream target genes FAS, SCD-1 (Fig. 17C, D). In 
addition, FGF1△HBS treatment increased expression of CPT-1α, PPARα, and PGC-1α 
(Fig. 17A, E-G), which were accompanied by significant upregulation of AMPK (Fig. 17A, 
H) and ACC (Fig. 17A, I) and SREBP-1 (Fig. 17A, J). These results suggest that 
FGF1ΔHBS reverses NAFLD in late-stage T2D through the similar molecular pathways as 






Fig. 14 The effects of FGF1△HBS on blood glucose and insulin sensitivity in 9-month-
old db/db mice. (A) The blood glucose over the course of 3 months treatment of db/db 
mice with FGF1△HBS (0.5 mg/kg body weight, every other day). (B and C) The Blood 
glucose levels in IPGTT and integrated area under the curve (AUC) for changes in blood 
















Fig.15 The therapeutic effects of FGF1△HBS on chronic NAFLD in 9-month old db/db 
mice. 9-month old db/db mice treated with FGF1△HBS (0.5 mg/kg, every other day) for 3 
months. (A and B) The liver size and weight. (C) Representative images of H&E-staining 
and Oil Red O staining of liver sections (magnification: X100). (D) Hepatic TG content in 
db/db mice.  (E and F) The serum ALT and AST. (G-J) Analysis for mRNA levels of hepatic 
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inflammatory marker (TNFα, PAI-1, ICAM-1 and VCAM-1).  Quantitative data are 
expressed as mean ± SEM, n=5-10. *P < 0.05 vs. db/db mice. 
 
 
Fig.16 FGF1△HBS reversed hepatic oxidative stress in 9-month old db/db mice. (A) 
The hepatic TG content in db/db mice.  (B) FGF1△HBS stimulated the Nrf2-mediated anti-
oxidative stress signaling genes in on chronic NAFLD in db/db mice. The protein 
expressions of n-Nrf2, CAT, HO-1 and NQO-1 were determined by Western blot. (C-F) The 
quantitative analysis of n-Nrf2, CAT, HO-1 and NQO-1 Western blot results by 






Fig.17 FGF1△HBS activated hepatic AMPK signaling pathway in 9-month old db/db 
mice.  (A) The expressions of AMPK signaling pathway related proteins (SREBP-1, FAS 
and SCD-1, CPT-1α, PGC-1α, PPARα, p-AMPK/AMPK, p-ACC and p-SREBP-1) were 
detected by Western blot. (B-J) The quantitative analysis of Western blot results by 
densitometry. Quantitative data are expressed as mean ± SEM, n=5-10. *P < 0.05 vs. 
db/db mice.  
 
DISSISION 
Consistent with the preventive effects of FGF1△HBS on early-stage db/db mice, here 
we clearly demonstrated that FGF1△HBS normalized blood glucose levels, improved insulin 
sensitivity and markedly prevented liver injury in these late-stage db/db mice, indicated by 
decreased hepatic TG levels, ALT and AST activity, and inflammatory marker expression 
(Fig. 14-15). These results validated the protection of FGF1△HBS against the late-stage 
NAFLD. Importantly, the mechanism studies showed that FGF1△HBS effectively activated 
AMPK-mediated Nrf2-antioxidative stress signaling pathways and lipid metabolic signaling 
pathways in those chronic liver diseases of aged db/db mice (Fig.16 and Fig. 17).    
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Combined with the preventive data found above, we demonstrate that FGF1△HBS 
could be promising candidate drug for prevention and therapeutic against NAFLD in T2D 











OVERALL DISCUSSION AND CONCLUSIONS 
 
Several studies have indicated the potential metabolic function of FGF1 in diabetes 
and steatosis. However, the use of FGF1 in the treatment of metabolic syndrome is still 
limited due to its undefined mechanism and its potential risk of tumorigenesis. The goals 
of the study in this dissertation are to evaluate the preventive and therapeutic effects of a 
novel FGF1 non-mitogenic variant, FGF1ΔHBS, on NAFLD in T2D, and to explore the 
underlying mechanisms. The outcomes of these studies strongly suggest that FGF1ΔHBS 
can be a promising therapeutic agent for NAFLD therapy in T2D. Our results can be 
summarized as follows: 
● FGF1△HBS treatment prevented the liver injury and inhibited the hepatic oxidative 
stress via activation of Nrf2-mediated antioxidative signaling pathways.  
● FGF1△HBS treatment reduced hepatic lipid accumulation by inhibiting lipogenesis 
and increasing fatty acid oxidation mediated via AMPK signaling pathways.   
● Nrf2 activation played an important role for the anti-oxidative effect of FGF1, but 
was not required for the protective effects of FGF1 against palmitate-induced 
lipid metabolic disorder in HepG2 cells.  
● AMPK played a critical role in FGF1 protection against Pal-induced oxidative 
stress and lipid disorder possibly via activating Nrf2-mediated antioxidative 




● FGF1△HBS completely reversed the phenotype of NAFLD along with activation 
on Nrf2 and AMPK signaling pathways in late-stage T2D. 
 
Overall discussion 
As discussed above, our study demonstrated that FGF1△HBS is a promising 
therapeutic agent in the prevention/treatment of NAFLD in T2D.  However, there are 
several limitations and questions remain to be answered. Some special findings should 
be further annotated: 
 
Whether the effect of FGF1 on NAFLD depends on its glucose lowering capability?  
In this dissertation, a typical type 2 diabetes model, db/db mice are chosen to 
explore the functions and mechanisms of FGF1 in NAFLD. FGF1△HBS treatment not only 
reverse the hepatic injuries but also significantly lower the blood glucose to the normal 
levels in db/db mice. One of the significant questions is if the effect of FGF1 on NAFLD 
depends on its glucose lowering ability. There are several possible explanations:     
a) To exclude the influence of blood glucose in vivo, our study used palmitate- 
treated hepatic cell culture in vitro models, which could determine the direct effect of FGF1 
on hepatocyte. The results suggested that FGF1 protected against the palmitate-induced 
oxidative stress and lipid disorder in both HepG2 cells and primary hepatocytes.   
b) Our previous study demonstrated that FGF1 could ameliorate diabetic 
nephropathy in both T1D and T2D even without any effect on the blood glucose levels in 
T1D, suggesting that FGF1 protection against DN was independent of its blood glucose 
lowering capacity(26).  
c) As described in the OVERVIEW, several studies have showed that FGF1 
exhibited protective effect against other diabetic complications in T1D without lowering the 
blood glucose. For examples, FGF1 ameliorated left ventricle dysfunction and reduced the
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myocardial apoptosis in diabetic cardiomyopathy of STZ-induced T1D(52, 53). FGF1 
promoted wound healing in diabetic ulcer of T1D by enhancing the expression of TGF-β 
and PCNA and inhibiting oxidative stress(41).  
Based on these studies, we speculate that the effect of FGF1△HBS on NAFLD is 
related to, but independent of its glucose lowering capability. NAFLD models without 
hyperglycemia should be considered to determine the direct effects and mechanisms of 
FGF1△HBS in fatty liver diseases in future studies. 
 
Whether FGF1 directly regulates hepatic de novo lipogenesis and fatty acid β-
oxidation in the protection against NAFLD? 
Several studies have demonstrated that exogenous excessive palmitate induced 
hepatic lipotoxicity, which was characterized by ROS accumulation, mitochondrial 
dysfunction, damaged fatty acid oxidation, and increased triglyceride accumulation(178, 179). 
This dissertation utilized this model to mimic diabetes-induced lipotoxicity in liver in T2D. 
Our results showed that both FGF1WT and FGF1△HBS prevented Pal-induced oxidative 
stress via upregulating Nrf2 mediated antioxidative signaling pathway and prevented Pal-
induced lipid metabolic disorder via increasing fatty acid oxidation and inhibiting the 
lipogenic signaling pathways. 
Although this dissertation and other previous studies have shown Pal treatment 
could induce hepatic lipogenesis and inhibit fatty acid  β-oxidation(159, 180, 181), this Pal-
induced model is not a direct and specific in vitro model to define the mechanism of FGF1 
in lipid metabolism, especially in de novo lipogenesis. Hepatic de novo lipogenesis is the 
biosynthetic process of fatty acids from acetyl‐CoA subunits that are produced from the 
dietary glucose, high‐carbohydrate or fructose(182). Many key enzymes and transcription 
factors, such as ACC, FAS, SREBP-1, are strongly involved in the de novo lipogenesis by 
converting the acetyl‐CoA into malonyl-CoA, subsequently, to fatty acids. Therefore, 
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glucose is the main and direct lipogenic substrate that drives de novo lipogenesis(66) and 
nutritionally regulate the key enzymes and transcription factors(183, 184). To fully understand 
the mechanism of FGF1 in regulating lipid metabolism, the high glucose plus insulin cell 
culture models(155, 185) should be considered in future studies.  
 
Whether AMPK plays a critical role in FGF1 protects against NAFLD in vivo? 
AMPK is a well-known central regulator and therapeutic target for many metabolic 
diseases. In addition to activating metabolic processes, AMPK inhibits inflammation, ER 
and oxidative stress, and activates autophagy(167). The question becomes whether AMPK 
plays a critical role in FGF1 protection against NAFLD in vivo.  
a) The metabolic functions of FGF1 are newly discovered and its target organs 
and/or tissues have not been clearly defined. This dissertation firstly indicated that FGF1 
significantly activated the phosphorylation of hepatic AMPK and its downstream genes in 
vivo and in vitro. Reference to the well-studied endocrine growth factor FGF21, its energy 
metabolic functions are strongly associated with AMPK pathways(72, 186). 
b) The present study also indicated that FGF1 inhibited the oxidative stress in 
NAFLD via activating Nrf2-mediated antioxidative signaling pathway. Recent studies 
suggested that Nrf2 is not only an important anti-oxidative factor, but also a potential target 
to the metabolic syndrome(137, 138). Distinguishing the functions between AMPK and Nrf2 
is important to define the targets for FGF1. According to previous studies, Nrf2 and AMPK 
can interact to regulate each other at different pathological and physiological conditions(87, 
117, 165, 187). According to our in vitro study, knockdown of AMPK in hepatocyte abolished 
both Nrf2-mediated anti-oxidative signaling pathway and SREBP-1-mediated lipid 
metabolic pathway, suggesting that AMPK is an upstream factor of Nrf2 and SREBP-1 for 
FGF1 protection against Pal-induce hepatic lipotoxicity. To elucidate the critical role of 
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AMPK in FGF1 protection against NAFLD, liver-specific AMPK knockout model could be 
considered in future studies.  
 
Which FGF receptor mediates the function of FGF1△HBS in the activation of AMPK 
against NAFLD? 
           FGFs carry out their diverse functions by binding and activating specific FGF 
receptors (FGFRs)(12). In addition, AMPK as a central metabolic sensor can be regulated 
by many major upstream kinases, such as liver kinase B1 (LKB1), calmodulin-dependent 
protein kinase kinase 2 (CaMKK2) and TGF-β-activated kinase (TAK1)(188, 189).  The goal 
of present study was not to define the binding partners of FGF1△HBS. However, several 
explanations are possible based on previous studies: 
a) As introduced in the OVERVIEW, FGF1 is considered the universal ligand that 
actively bind to the four different FGFRs (FGFR1–FGFR4)(9, 10). FGFR1–FGFR4 are 
positively expressed in normal liver(190) and these receptors-mediated signaling pathways 
are essential for liver pathophysiology(191). In hepatocytes, FGFR4 is the most abundant 
FGFR that acts as a regulator of bile acid homeostasis and protects liver from fibrosis(192).  
Loss or overexpression of FGFR1, FGFR2 and FGFR3 in hepatocytes also strongly 
impairs the liver homeostasis and regeneration(191, 193) (194).  
b) Previous studies suggested that the endocrine FGF15/19 acts on the 
FGFR4/βKlotho complex showing the beneficial effects on liver metabolism. however, it 
also stimulated hepatocyte proliferation through an FGFR4-dependent mechanism(195). 
Meanwhile, FGFR1c isoform is important for the in vivo actions of endocrine FGF21. A 
previous study showed that the endocrine FGF21 activated the AMPK signaling pathway 
in the target tissues through FGFR1/β-klotho signaling directly(196).  
c) Recent study showed that the blood glucose-lowering effects of FGF1 were 
mediated through FGFR1, FGF1 failed to lower glucose levels in the FGFR1 knockout 
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mice(9). Consistent with this, a FGF1 analogue FGF1ΔNT (FGF1 L29–D155) similarly failed 
to affect blood glucose levels in FGFR1 knockout mice(9), further supporting the notion that 
FGFR1-mediated signaling is required for the glucose-lowering effects of parenteral 
FGF1(9).  
d) In our previous study, we found that compared to the FGF1WT, FGF1△HBS  
diminished its ability to induce heparan sulfate-assisted FGFR1 dimerization and 
activation, resulting in a diminished ability to induce FRS2 phosphorylation, the major 
substrate of FGFRs, and the downstream ERK activation, in both adipoctyes and 
hepatocytes(85).  
Taken together, we speculate that FGFR1 is the major receptor mediating the 
metabolic function of FGF1 in liver, as well as in adipose tissue, which needs to be verified 
in future studies.  
 
The optimal dose of FGF1△HBS 
The dose-response results in our previous study clearly showed that an acute 
injection of FGF1WT and FGF1△HBS at the dose of 0.5 mg/kg body weight significantly 
lowered blood glucose levels, and this effect lasted up to to 24 hours in db/db mice without 
further lowering effects by increasing the dose to 1 mg/kg body weight(85). Furthermore, 
treatment of db/db mice with FGF1WT and FGF1△HBS at a dose of 0.5 mg/kg every other 
day for 4 weeks resulted in the sustained glucose lowering and attenuating the hepatic 
steatosis(85). Hence, FGF1△HBS delivery at the dose of 0.5mg/kg every other day was 
applied in the present study. However, this dose might not be the optimal one for liver 
protection, although we observed that FGF1△HBS at the dose of 0.5 mg/kg exhibited an 
antisteatotic effect. To achieve the optimal effects and establish the fundamental dose 
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regime for future FGF1△HBS clinical use, the dose- and time-dependent effects of FGF1△HBS 
on the prevention and reversal of NAFLD need to be addressed in future studies.    
 
Innovations  
The innovations in this dissertation can be summarized as follows： 
● FGF1△HBS can effectively prevent and reverse NAFLD by inhibiting oxidative stress 
and regulating lipid metabolism in T2D. 
● AMPK may be a novel therapeutic target for FGF1△HBS prevention and reversal of 
NAFLD. 
● The novel non-mitogenic variant FGF1△HBS may be an effective and safe 




As above discussed, several limitations should be clarified in this dissertation. 
1) NAFLD model: to elucidate the direct functions and mechanisms of FGF1 in the 
fatty liver, non-diabetic NAFLD models are needed in the future study.  
2) Cell culture model: to understand the mechanism of FGF1 regulating lipid 
metabolism, the high glucose plus insulin-induced cell model should be considered. 
3) Hepatic AMPK inactive model: to dissect the critical role of AMPK in FGF1 
protection against NAFLD, liver specific AMPK knockout model should be used.  







● Mechanistic study: In addition to regulating lipid metabolism in NAFLD of T2D, 
FGF1 is a potent insulin sensitizer that lowers the blood glucose and increases the insulin 
sensitivity in diabetes. The understanding of how FGF1 increases insulin sensitivity, as 
well as how FGF1 regulates glucose and lipid metabolism will be the key objects in our 
future studies.  
● Clinical translation: this dissertation demonstrates that the novel non-mitogenic 
variant FGF1△HBS is a promising candidate drug to replace FGF1WT to treat NAFLD in T2D 
without the risk of tumorigenesis. We will continually explore its potential for preventing 
other metabolic syndrome and their complications, such as obesity, and diabetic 
cardiovascular diseases in animals and even apply for a phase I clinical observation for 
the prevention of NAFLD for T2D patients.  
 
Conclusion 
In summary, our findings indicate that, in addition to its potent glucose-lowering and 
insulin-sensitizing effects, the novel non-mitogenic variant FGF1△HBS has not only 
preventive and but therapeutic effects on NAFLD in T2D via effectively inhibiting oxidative 
stress and improving lipid metabolism, which shows a great potential to replace the use 
of FGF1WT to treat NAFLD in diabetes. Importantly, our studies provide new insight into 
the mechanisms by which FGF1△HBS prevents hepatic oxidative stress and steatosis in 
T2D. AMPK, that activates Nrf2-mediated antioxidative pathway and inhibits SREBP-1-
mediated lipid metabolic pathway, is a critical target for FGF1 protection against NAFLD 
in T2D (Fig. 18). From our perspective, a full understanding of FGF1 function in metabolic 
disorders requires further investigation of the multiple aspects of roles of AMPK or other 
molecular targets in these pathophysiological processes. This project provides 
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fundamental evidence for FGF1 as a novel therapeutic approach to prevention of NAFLD 
via activating hepatic AMPK.  
 
 
Fig. 18 A mechanistic illustration of FGF1 preventing diabetes-induced hepatic 
oxidative stress and lipid disorder via activating AMPK signaling pathways. FGF1 activates 
AMPK-mediated lipid metabolism and anti-oxidative stress signaling via inhibiting the lipid 
accumulation and upregulating lipid oxidation, as well as Nrf2-mediated anti-oxidative 
signaling pathway, thus prevents diabetes-induced hepatic lipid disorder and oxidative 
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LIST OF ABBREVIATIONS 
FGF1: Fibroblast Growth Factor 1 
T2D: Type 2 Diabetes 
NAFLD: Nonalcoholic Fatty Liver Disease 
Nrf2: Nuclear Factor Erythroid 2-Related Factor 2 




HO-1: Heme Oxygenase 1 (HO1) 
NQO1:  NAD(P)H Quinone Oxidase 1 
CAT: Catalase 
ALT: Alanine Aminotransferase 
AST: Aspartate Aminotransferase 
TG: Triglyceride 
AMPK: AMP-activated protein kinase 
ACC: Acetyl-CoA Carboxylase 
SREBP-1: Sterol Regulatory Element-Binding Protein-1  
FAS: Fatty Acid Synthase 
SCD-1: Stearoyl-CoA desaturase-1 
CPT-1α: Carnitine Palmitoyltransferase I α  
PPARα: Peroxisome Proliferator-Activated Receptor α 
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HONORS AND AWARDS 
2016   Graduate Students Poster Award (Third Place), presented by the Ohio Valley 
           Society of Toxicology Annual Meeting (OVSOT), October 28th, 2016. Eli Lilly 
           Campus. Awardee: Qian Lin. Mentor: Yi Tan.  
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2017   Renal Toxicology Award (2nd Place), presented by the Mechanisms Specialty 
Section, the Society of Toxicology (SOT) 56th Annual Meeting and ToxExpo. 
Baltimore, Maryland, March 12–16, 2017. Awardee: Qian Lin. Mentor: Yi Tan. 
2017   Graduate Student Travel Award, presented by the Society of Toxicology (SOT) 
56th Annual Meeting and ToxExpo. Baltimore, Maryland, March 12–16, 2017. 
Awardee: Qian Lin. Mentor: Yi Tan. 
2017 Outstanding Young Investigator Award (First Prize), Recognition of outstanding 
research and scientific presentation at the Fourth ACRE-APS symposium, July 
09, 2017 in Portland, Oregon. Awardee: Qian Lin. Mentor: Yi Tan. 
2018   Student Presentation Award, presented by the 9th Scientific Symposium, 
Chinese-American Diabetes Association. June 20-22, 2018, Hyatt Place 
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2018   Ronald G.Thurman Student Travel Award, presented by the Mechanisms 
Specialty Section at the Society of Toxicology (SOT) 57th Annual Meeting and 
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Functional and pathological improvements of the hearts in diabetes model by the 
combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted 
microbubble destruction. J Control Release. 2014; 186:22-31.  
2. Lu CT#, Jin RR#, Jiang YN, Lin Q, Yu WZ, Mao KL, Tian FR, Zhao YP*, Zhao YZ*. 
Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 
6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study. Drug Des 
Devel Ther. 2015; 9:1955-62. 
3. Zhao YZ#, Jin RR#, Yang W, Xiang Q, Yu WZ, Lin Q, Tian FR, Mao KL, Lv CZ, 
Wáng YX, Lu CT*. Using Gelatin Nanoparticle Mediated Intranasal Delivery of 
Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats. 
PLoS One. 2016; 19;11(2): e0148848.  
4. Xu Z#, Sun J#, Tong Q#, Lin Q, Qian L, Park Y*, Zheng Y*. The Role of ERK1/2 in 
the Development of Diabetic Cardiomyopathy. Int J Mol Sci. 2016; 17(12). 
Review.  
5. Zhao YZ#, Jiang X#, Xiao J#, Lin Q, Yu WZ, Tian FR, Mao KL, Yang W, Wong HL*, 
Lu CT*. Using NGF heparin-poloxamer thermosensitive hydrogels to enhance the 
nerve regeneration for spinal cord injury. Acta Biomater. 2016; 29:71-80. 
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Zhao YZ*. Enhanced neuroprotection with decellularized brain extracellular matrix 
containing bFGF after intracerebral transplantation in Parkinson's disease rat 
model. Int J Pharm. 2017; 517(1-2): 383-394.  
12. Yan X#, Wu L, Lin Q, Dai X, Hu H, Wang K, Zhang C, Shao M, Cai L, Tan Y*. 
Alcohol Inhibition of the Enzymatic Activity of Glyceraldehyde 3-Phosphate 
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Dehydrogenase Impairs Cardiac Glucose Utilization, Contributing to Alcoholic 
Cardiomyopathy. Toxicol Sci. 2017; 159(2):392-401.  
13. Huang Z#, Tan Y#, Gu J#, Liu Y, Song L, Niu J, Zhao L, Srinivasan L, Lin Q, Deng 
J, Li Y, Conklin DJ, Neubert TA, Cai L, Li X*, Mohammadi M*. Uncoupling the 
Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer 
Stability. Cell Rep. 2017, 20(7):1717-1728.  
14. Liang G#, Song L#, Chen Z#, Qian Y, Xie J, Zhao L, Lin Q, Zhu G, Tan Y, Li X, 
Mohammadi M, Huang Z*. Fibroblast growth factor 1 ameliorates diabetic 
nephropathy by an anti-inflammatory mechanism. Kidney Int. 2018,93(1):95-109. 
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endothelial progenitor cell function via augmenting autophagy enhances ischaemic 
angiogenesis in diabetes. J Cell Mol Med. 2018; 22(1):89-100.  
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National/International/Regional Meetings 
2017   Fibroblast Growth Factor 1 Prevents Diabetic Nephropathy Through an Anti-
JNK/NF-κB Signal pathway. The 8th Scientific Symposium of the Chinese-
American Diabetes Association (CADA), June 8-9, 2017 in San Diego, California.  
2017   Fibroblast Growth Factor 1 Prevents Diabetic Nephropathy Through an Anti-
JNK/NF-κB Signal pathway. American Diabetes Association 77th Scientific 
Sessions (ADA), June 9 - 13, 2017, San Diego, California. 
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2017 Fibroblast Growth Factor 1 Prevents Diabetic Nephropathy Through an Anti-
JNK/NF-κB Signal pathway. The Fourth ACRE-APS symposium, July 09, 2017 in 
Portland, Oregon.  
2018   A novel fibroblast growth factor 1 variant reverses nonalcoholic fatty liver disease 
in type 2 diabetes. Pediatric Research Institute-WIP, Department of Pediatrics, 
University of Louisville. March 31, 2018, Louisville, KY 
2018   A novel fibroblast growth factor 1 variant reverses nonalcoholic fatty liver disease 
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(SOT) 57th Annual Meeting, Mar 11 - 15, 2018, San Antonio, Texas.  
2. Qian Lin, Paul N. Epstein, Lu Cai1, Yi Tan. A novel fibroblast growth factor 1 variant 
reverses nonalcoholic fatty liver disease in type 2 diabetes. The American Diabetes 
Association 78th Scientific Sessions, June 22-26, 2018 in Orlando, Florida. 
 
 
 
